<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">58039</article-id><article-id pub-id-type="doi">10.7554/eLife.58039</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>G protein-regulated endocytic trafficking of adenylyl cyclase type 9</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-184551"><name><surname>Lazar</surname><given-names>André M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3372-3742</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-184552"><name><surname>Irannejad</surname><given-names>Roshanak</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8702-2285</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-184553"><name><surname>Baldwin</surname><given-names>Tanya A</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-184554"><name><surname>Sundaram</surname><given-names>Aparna B</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-4076-4756</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-184555"><name><surname>Gutkind</surname><given-names>J Silvio</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-184556"><name><surname>Inoue</surname><given-names>Asuka</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-39361"><name><surname>Dessauer</surname><given-names>Carmen W</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-164268"><name><surname>Von Zastrow</surname><given-names>Mark</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1375-6926</contrib-id><email>mark@vzlab.org</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Program in Biochemistry and Cell Biology, University of California San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Cardiovascular Research Institute and Department of Biochemistry and Biophysics, University of California San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Department of Integrative Biology and Pharmacology, University of Texas Health Science Center</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Lung Biology Center, Department of Medicine, University of California San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>Department of Pharmacology and Moores Cancer Center, University of California San Diego</institution><addr-line><named-content content-type="city">San Diego</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>Graduate School of Pharmaceutical Sciences, Tohoku University, Aoba-ku</institution><addr-line><named-content content-type="city">Sendai</named-content></addr-line><country>Japan</country></aff><aff id="aff7"><label>7</label><institution>Department of Psychiatry and Department of Cellular and Molecular Pharmacology, University of California San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Linstedt</surname><given-names>Adam</given-names></name><role>Reviewing Editor</role><aff><institution>Carnegie Mellon University</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Pfeffer</surname><given-names>Suzanne R</given-names></name><role>Senior Editor</role><aff><institution>Stanford University School of Medicine</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>09</day><month>06</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e58039</elocation-id><history><date date-type="received" iso-8601-date="2020-04-20"><day>20</day><month>04</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-06-08"><day>08</day><month>06</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Lazar et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Lazar et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-58039-v2.pdf"/><abstract><p>GPCRs are increasingly recognized to initiate signaling via heterotrimeric G proteins as they move through the endocytic network, but little is known about how relevant G protein effectors are localized. Here we report selective trafficking of adenylyl cyclase type 9 (AC9) from the plasma membrane to endosomes while adenylyl cyclase type 1 (AC1) remains in the plasma membrane, and stimulation of AC9 trafficking by ligand-induced activation of Gs-coupled GPCRs. AC9 transits a similar, dynamin-dependent early endocytic pathway as ligand-activated GPCRs. However, unlike GPCR traffic control which requires β-arrestin but not Gs, AC9 traffic control requires Gs but not β-arrestin. We also show that AC9, but not AC1, mediates cAMP production stimulated by endogenous receptor activation in endosomes. These results reveal dynamic and isoform-specific trafficking of adenylyl cyclase in the endocytic network, and a discrete role of a heterotrimeric G protein in regulating the subcellular distribution of a relevant effector.</p></abstract><abstract abstract-type="executive-summary"><title>eLife digest</title><p>Cells sense changes in their chemical environment using proteins called receptors. These proteins often sit on the cell surface, detecting molecules outside the cell and relaying messages across the membrane to the cell interior. The largest family of receptors is formed of ‘G protein-coupled receptors’ (or GPCRs for short), so named because they relay messages through so-called G proteins, which then send information into the cell by interacting with other proteins called effectors. Next, the receptors leave the cell surface, travelling into the cell in compartments called endosomes. Researchers used to think that this switched the receptors off, stopping the signaling process, but it is now clear that this is not the case. Some receptors continue to signal from inside the cell, though the details of how this works are unclear.</p><p>For signals to pass from a GPCR to a G protein to an effector, all three proteins need to be in the same place. This is certainly happening at the cell surface, but whether all three types of proteins come together inside endosomes is less clear. One way to find out is to look closely at the location of effector proteins when GPCRs are receiving signals. One well-studied effector of GPCR signaling is called adenylyl cyclase, a protein that makes a signal molecule called cAMP. Some G proteins switch adenylyl cyclase on, increasing cAMP production, while others switch it off.</p><p>To find out how GPCRs send signals from inside endosomes, Lazar et al tracked adenylyl cyclase proteins inside human cells. This revealed that a type of adenylyl cyclase, known as adenylyl cyclase 9, follows receptors as they travel into the cell. Under the influence of active G proteins, activated adenylyl cyclase 9 left the cell surface and entered the endosomes. Once inside the cell, adenylyl cyclase 9 generated the signal molecule cAMP, allowing the receptors to send messages from inside the cell. Other types of adenylyl cyclase behaved differently. Adenylyl cyclase 1, for example, remained on the cell surface even after its receptors had left, and did not signal from inside the cell at all.</p><p>Which cell behaviors are triggered from the membrane, and which are triggered from inside the cell is an important question in drug design. Understanding where effector proteins are active is a step towards finding the answers. This could help research into diseases of the heart, the liver and the lungs, all of which use adenylyl cyclase 9 to send signals.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>GPCR</kwd><kwd>G protein</kwd><kwd>adenyl cyclase</kwd><kwd>cyclic AMP</kwd><kwd>trafficking</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>DA010154</award-id><principal-award-recipient><name><surname>Von Zastrow</surname><given-names>Mark</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>DA012864</award-id><principal-award-recipient><name><surname>Von Zastrow</surname><given-names>Mark</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>GM60419</award-id><principal-award-recipient><name><surname>Dessauer</surname><given-names>Carmen W</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>HL124049</award-id><principal-award-recipient><name><surname>Sundaram</surname><given-names>Aparna B</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>CA209891</award-id><principal-award-recipient><name><surname>Gutkind</surname><given-names>J Silvio</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>HL122508</award-id><principal-award-recipient><name><surname>Irannejad</surname><given-names>Roshanak</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>GM133521</award-id><principal-award-recipient><name><surname>Irannejad</surname><given-names>Roshanak</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>An adenylyl cyclase isoform is shown to dynamically traffic to endosomes after activation by G protein in mammalian cells, contributing to cellular cAMP signaling by internalized GPCRs.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>G protein-coupled receptors (GPCRs) comprise nature’s largest family of signaling receptors and an important class of therapeutic targets (<xref ref-type="bibr" rid="bib39">Lefkowitz, 2007</xref>; <xref ref-type="bibr" rid="bib56">Rosenbaum et al., 2009</xref>). GPCRs are so-named because a major mechanism by which they mediate transmembrane signaling is through ligand-dependent activation of heterotrimeric G proteins that act as intracellular signal transducers (<xref ref-type="bibr" rid="bib19">Gilman, 1987</xref>; <xref ref-type="bibr" rid="bib25">Hilger et al., 2018</xref>; <xref ref-type="bibr" rid="bib61">Spiegel, 1987</xref>; <xref ref-type="bibr" rid="bib65">Stryer and Bourne, 1986</xref>; <xref ref-type="bibr" rid="bib66">Sunahara et al., 1996</xref>). This conserved signaling cascade invariably requires one additional component, an ‘effector’ protein which is regulated by the G protein to convey the signal downstream (<xref ref-type="bibr" rid="bib12">Dessauer et al., 1996</xref>; <xref ref-type="bibr" rid="bib19">Gilman, 1987</xref>; <xref ref-type="bibr" rid="bib56">Rosenbaum et al., 2009</xref>). Ligand-activated GPCR - G protein - effector cascades were thought for many years to be restricted to the plasma membrane, with endocytosis considered only in the context of signal termination and homeostatic down-regulation of receptors. This view has expanded over the past several years, driven by accumulating evidence that ligand-dependent GPCR and G protein activation processes can also occur from internal membrane compartments including endosomes (<xref ref-type="bibr" rid="bib13">Di Fiore and von Zastrow, 2014</xref>; <xref ref-type="bibr" rid="bib31">Irannejad et al., 2015</xref>; <xref ref-type="bibr" rid="bib32">Jong et al., 2018</xref>; <xref ref-type="bibr" rid="bib40">Lobingier and von Zastrow, 2019</xref>; <xref ref-type="bibr" rid="bib42">Lohse and Calebiro, 2013</xref>; <xref ref-type="bibr" rid="bib43">Lohse and Hofmann, 2015</xref>; <xref ref-type="bibr" rid="bib78">Vilardaga et al., 2014</xref>).</p><p>The beta-2 adrenergic receptor (β2AR) provides a clear example, and is generally considered a model for the GPCR family more broadly (<xref ref-type="bibr" rid="bib39">Lefkowitz, 2007</xref>; <xref ref-type="bibr" rid="bib56">Rosenbaum et al., 2009</xref>). β2ARs initiate signaling in response to binding of an agonist ligand by activating ('coupling' to) the stimulatory heterotrimeric G protein, Gs, at the plasma membrane. β2ARs then internalize through agonist-dependent accumulation into clathrin-coated pits, efficiently recycle and transit continuously between the plasma membrane and endosomes in the prolonged presence of agonist (<xref ref-type="bibr" rid="bib81">von Zastrow and Kobilka, 1994</xref>; <xref ref-type="bibr" rid="bib80">von Zastrow and Kobilka, 1992</xref>). Agonist-induced clustering of β2ARs into coated pits, the process initiating this cycle, is promoted by receptor phosphorylation and binding to β-arrestins at the plasma membrane (<xref ref-type="bibr" rid="bib15">Ferguson et al., 1996</xref>; <xref ref-type="bibr" rid="bib21">Goodman et al., 1996</xref>). These events were shown previously to inhibit β2AR coupling to Gs (<xref ref-type="bibr" rid="bib41">Lohse et al., 1990</xref>), and β2AR inactivation was recognized to precede removal from the cell surface even before this mechanistic elucidation (<xref ref-type="bibr" rid="bib24">Harden et al., 1980</xref>). Accordingly, it was believed for many years that β2ARs are unable to engage G proteins once internalized. This view changed with the finding that β2ARs reacquire functional activity shortly after arriving in the limiting membrane of early endosomes, and then activate Gs again from this location (<xref ref-type="bibr" rid="bib30">Irannejad et al., 2013</xref>). A number of GPCRs have now been shown to activate Gs after endocytosis, initiating a discrete ‘second wave’ of downstream signaling which varies in magnitude and duration depending (in part) on the residence time of activated receptors in the endocytic network (<xref ref-type="bibr" rid="bib31">Irannejad et al., 2015</xref>; <xref ref-type="bibr" rid="bib42">Lohse and Calebiro, 2013</xref>; <xref ref-type="bibr" rid="bib73">Thomsen et al., 2016</xref>; <xref ref-type="bibr" rid="bib74">Tian et al., 2016</xref>; <xref ref-type="bibr" rid="bib77">Varandas et al., 2016</xref>; <xref ref-type="bibr" rid="bib78">Vilardaga et al., 2014</xref>).</p><p>Gs transduces downstream signaling by stimulating adenylyl cyclases (ACs) to produce cyclic AMP (cAMP), an important diffusible mediator (<xref ref-type="bibr" rid="bib43">Lohse and Hofmann, 2015</xref>; <xref ref-type="bibr" rid="bib67">Sutherland, 1971</xref>; <xref ref-type="bibr" rid="bib70">Taylor et al., 2013</xref>), and studies of cAMP signaling provided much of the initial evidence supporting the potential of GPCRs to mediate ligand-dependent signaling via G proteins after endocytosis (<xref ref-type="bibr" rid="bib5">Calebiro et al., 2009</xref>; <xref ref-type="bibr" rid="bib10">Clark et al., 1985</xref>; <xref ref-type="bibr" rid="bib16">Ferrandon et al., 2009</xref>; <xref ref-type="bibr" rid="bib36">Kotowski et al., 2011</xref>; <xref ref-type="bibr" rid="bib48">Mullershausen et al., 2009</xref>; <xref ref-type="bibr" rid="bib58">Slessareva et al., 2006</xref>). Nine transmembrane AC isoforms are conserved in mammals, each stimulated by Gs but differing in regulation by other G proteins and signaling intermediates, and multiple AC isoforms are typically coexpressed in tissues (<xref ref-type="bibr" rid="bib57">Sadana and Dessauer, 2009</xref>; <xref ref-type="bibr" rid="bib66">Sunahara et al., 1996</xref>; <xref ref-type="bibr" rid="bib82">Wang et al., 2019</xref>). Biochemical and structural aspects of regulated cAMP production by ACs have been extensively studied but much less is known about the cellular biology of ACs.</p><p>According to the present understanding, GPCR-stimulated cAMP production requires all three ‘core’ components of the signaling cascade – the GPCR, Gs and AC – to be in the same membrane bilayer (<xref ref-type="bibr" rid="bib20">Gilman, 1989</xref>). Whereas GPCRs and Gs are well known to undergo dynamic redistribution between the plasma membrane and endocytic membranes (<xref ref-type="bibr" rid="bib1">Allen et al., 2005</xref>; <xref ref-type="bibr" rid="bib26">Hynes et al., 2004</xref>; <xref ref-type="bibr" rid="bib31">Irannejad et al., 2015</xref>; <xref ref-type="bibr" rid="bib45">Marrari et al., 2007</xref>; <xref ref-type="bibr" rid="bib80">von Zastrow and Kobilka, 1992</xref>; <xref ref-type="bibr" rid="bib83">Wedegaertner et al., 1996</xref>), the subcellular localization and trafficking properties of transmembrane ACs remain largely unknown. Nevertheless, adenylyl cyclase activity was noted on intracellular membranes many years ago (<xref ref-type="bibr" rid="bib9">Cheng and Farquhar, 1976</xref>) and more recent studies have implicated several AC isoforms in GPCR-regulated cAMP production from endomembrane compartments (<xref ref-type="bibr" rid="bib5">Calebiro et al., 2009</xref>; <xref ref-type="bibr" rid="bib6">Cancino et al., 2014</xref>; <xref ref-type="bibr" rid="bib16">Ferrandon et al., 2009</xref>; <xref ref-type="bibr" rid="bib27">Inda et al., 2016</xref>; <xref ref-type="bibr" rid="bib36">Kotowski et al., 2011</xref>; <xref ref-type="bibr" rid="bib78">Vilardaga et al., 2014</xref>). Key knowledge gaps at the present frontier are how ACs localize to relevant internal membranes, if the subcellular localization of ACs is selective between isoforms, and if this localization is regulated. Here we report initial inroads into this frontier by demonstrating the dynamic and isoform-specific endocytic trafficking of AC9, and its ligand-dependent regulation through Gs.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Regulated and isoform-selective trafficking of AC9 to endosomes</title><p>Human embryonic kidney (HEK293) cells comprise a well established model system for investigating GPCR signaling via the cAMP cascade, particularly signaling initiated by β2ARs which are endogenously expressed in these cells (<xref ref-type="bibr" rid="bib79">Violin et al., 2008</xref>). The β2AR stimulates cAMP production primarily from the plasma membrane, with endosomal activation contributing a relatively small but functionally significant fraction (<xref ref-type="bibr" rid="bib30">Irannejad et al., 2013</xref>; <xref ref-type="bibr" rid="bib76">Tsvetanova and von Zastrow, 2014</xref>). In a similar vein, AC3 and AC6 are the most highly expressed AC isoforms and are major producers of global cAMP in these cells, while AC1 and AC9 transcripts are expressed at only moderately reduced levels and comparable to one another (<xref ref-type="bibr" rid="bib60">Soto-Velasquez et al., 2018</xref>). This prompted us to ask whether AC1 and/or AC9 might be relevant to generating the fraction of cellular cAMP produced by β2AR activation in endosomes.</p><p>As a first step to investigate this hypothesis, we examined the subcellular localization of AC1 and AC9 using a recombinant epitope tagging strategy, beginning with AC1 because this isoform was shown previously to tolerate an N-terminal Flag tag (<xref ref-type="bibr" rid="bib8">Chen et al., 1997</xref>). When expressed in HEK293 cells, Flag-tagged AC1 (Flag-AC1) localized primarily to the plasma membrane, similar to a co-expressed HA-tagged β2AR construct (HA-β2AR). Application of the β-adrenergic agonist isoproterenol promoted HA-β2ARs to redistribute within minutes to cytoplasmic punctae, as described previously, but Flag-AC1 remained at the plasma membrane (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). While clearly resolved in confocal sections, this difference in localization was sufficiently strong to be evident in lower-magnification widefield images surveying many cotransfected cells (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>). We assessed reproducibility of this effect in two ways. First, we determined the number of internal punctae per cell in which HA-β2AR and Flag-AC1 colocalized. Second, we determined the fraction of cells visualized in each microscopic field that contained at least 10 such punctae. Both metrics verified selective internalization of the β2AR but not AC1 (<xref ref-type="fig" rid="fig1">Figure 1C and D</xref>, left set of bars).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>β2AR activation promotes redistribution of AC9 but not AC1.</title><p>(<bold>A</bold>) Representative confocal imaging of HEK293 cells coexpressing HA-β2AR and Flag-AC1 after treatment with 10 µM isoproterenol or control for 30 min. Scale Bar is 8 µm. (<bold>B</bold>) Representative confocal images of HEK293 cells coexpressing HA-β2AR and Flag-AC9 after treatment with 10 µM isoproterenol or control for 30 min. Scale Bar is 8 µm. (<bold>C</bold>) Quantification of internal puncta that are β2AR or AC1/9 positive, taken from wide field images (see <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D and E</xref>) [mean ± SEM; n = 3 experiments, 10 visual fields and 200+ cells per condition]. **p&lt;0.01 by two-tailed t-test. (<bold>D</bold>) Quantification of cells with &gt;10 internal puncta that are β2AR or AC1/9 positive, taken from wide field images (see <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D andE</xref>) [mean ± SEM; n = 3 experiments, 10 visual fields and 200+ cells per condition]. **p&lt;0.01 by two-tailed t-test. (<bold>E–F</bold>) Representative confocal imaging of HEK293 cells expressing Flag-AC1 (<bold>E</bold>) or Flag-AC9 (<bold>F</bold>) after treatment with 10 µM isoproterenol or control for 30 min. Scale Bar is 8 µM. (<bold>G–H</bold>) Representative confocal imaging of HEK293 cells expressing Flag-AC1 (<bold>G</bold>) or Flag-AC9 (<bold>H</bold>). Cells were stimulated with 100 nM isoproterenol for 30 min with or without 15 min of pretreatment with 10 µM alprenolol. (<bold>I</bold>) Representative confocal images of primary culture human airway smooth muscle cells immunostained for endogenous AC9 after treatment with 10 µM isoproterenol or control for 30 min. Scale Bar is 16 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58039-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Functional validation of Flag-tagged AC9 and quantification of isoform-specific localization to endosomes.</title><p>(<bold>A</bold>) Quantification of the in vitro cAMP response by pcDNA3 control, untagged AC9, and Flag-tagged AC9 to 300 nM Gs (alpha subunit). (<bold>B</bold>) Quantification of the cAMP response to 10 µM isoproterenol in control HEK293 cells and cells overexpressing Flag-AC1, Flag-AC9, or Flag-AC9-D442A by ELISA assay. [mean ± SEM; n = 3 experiments] (<bold>C</bold>) Quantification of the number of endosomes in cells from (<xref ref-type="fig" rid="fig1">Figure 1E–H</xref>) [mean ± SEM; n = 3 experiments, 25 cells per condition]. (<bold>D</bold>) Wide field images of HEK293 cells coexpressing HA-β2AR and Flag-AC9, after treatment with 10 µm isoproterenol or control for 30 min. Scale bar is 16 µm. (<bold>E</bold>) Wide field images of HEK293 cells coexpressing HA-β2AR and Flag-AC1, after treatment with 10 µm isoproterenol or control for 30 min. Scale bar is 16 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58039-fig1-figsupp1-v2.tif"/></fig></fig-group><p>We applied a similar tagging strategy to AC9 and verified that Flag tagging also does not disrupt the functional activity of AC9 (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A,B</xref>). Flag-AC9 localized predominantly in the plasma membrane in the absence of agonist, similar to Flag-AC1. However, after application of isoproterenol, Flag-AC9 redistributed to intracellular punctae, the majority of which also contain internalized HA-β2AR (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Punctate redistribution of both Flag-AC9 and HA-β2AR was also evident in lower-magnification widefield images (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>) and was verified quantitatively (<xref ref-type="fig" rid="fig1">Figure 1C and D</xref>, right set of bars). AC9 labeled in its C-terminal cytoplasmic domain with GFP (AC9-GFP) also redistributed, enabling live-cell confocal imaging which revealed mobile AC9-containing endosomes (<xref ref-type="video" rid="video1">Video 1</xref>). These results indicate that AC9 traffics dynamically to endosomes containing β2ARs, this trafficking is isoform-specific because AC1 remains in the plasma membrane, and it is regulated because AC9 accumulation in endosomes is increased by β2AR activation.</p><media id="video1" mime-subtype="mp4" mimetype="video" xlink:href="elife-58039-video1.mp4"><label>Video 1.</label><caption><title>This movie shows a confocal image series of AC9-EGFP overexpressed in a HEK293 cell.</title><p>Cell was treated with 10 µM isoproterenol added at t = 0 in the time stamp. AC9 recruitment to internal puncta is observed over the course of 30 min.</p></caption></media><p>Isoproterenol also stimulated selective internalization of Flag-AC9 in the absence of recombinant β2AR overexpression (<xref ref-type="fig" rid="fig1">Figure 1E and F</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>) and this effect was blocked by the β-adrenergic antagonist alprenolol (<xref ref-type="fig" rid="fig1">Figure 1G and H</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). These results indicate that endogenous β2AR activation is sufficient to stimulate AC9 trafficking and this is not an off-target drug effect. AC9, and ACs in general, are naturally expressed in low abundance. We were unable to reliably detect endogenous AC9 in HEK293 cells using available antibodies, but endogenous AC9 was detectable in primary human airway smooth muscle cells that naturally coexpress β2ARs (<xref ref-type="bibr" rid="bib3">Billington et al., 1999</xref>). Endogenous AC9 immunoreactivity localized in these cells primarily to the plasma membrane under basal conditions, and its localization to internal punctae increased after isoproterenol application (<xref ref-type="fig" rid="fig1">Figure 1I</xref>). These results suggest that the trafficking behavior revealed by study of recombinant, tagged AC9 is relevant to the native protein.</p></sec><sec id="s2-2"><title>AC9 traffics via a similar pathway as β2AR but is differentially regulated</title><p>Internalized β2ARs accumulate in endosomes marked by Early Endosome Antigen 1 (EEA1) and agonist-dependent activation of Gs by the β2AR occurs on this compartment (<xref ref-type="bibr" rid="bib30">Irannejad et al., 2013</xref>). We verified isoform-specific localization of Flag-AC9 but not Flag-AC1 to EEA1-marked endosomes by confocal microscopy (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>) and then applied anti-EEA1 immunoisolation (<xref ref-type="bibr" rid="bib11">Cottrell et al., 2009</xref>; <xref ref-type="bibr" rid="bib23">Hammond et al., 2010</xref>; <xref ref-type="bibr" rid="bib71">Temkin et al., 2011</xref>) to purify these endosomes and probe their composition. Coexpressed HA-β2AR and Flag-AC9 were enriched in the endosome fraction prepared from isoproterenol-treated cells, as detected by immunoblot analysis and verified quantitatively across multiple experiments. In contrast, HA-β2AR but not Flag-AC1 was enriched in parallel isolations from cells co-expressing HA-β2AR and Flag-AC1, with similar levels of overall expression across both cell populations verified in cell lysates (<xref ref-type="fig" rid="fig2">Figure 2C,D</xref>, and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). Documenting separation efficiency and fraction purity, the endosome fraction recovered ~34% of total cellular EEA1 but <underline>&lt;</underline>5% of Golgi, endoplasmic reticulum, or plasma membrane markers (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>AC9 undergoes dynamin-dependent endocytosis and accumulates in endosomes marked by EEA1.</title><p>(<bold>A–B</bold>) Representative confocal images of HEK293 cells expressing Flag-AC1 (<bold>A</bold>) or Flag-AC9 (<bold>B</bold>) after treatment with 10 µM isoproterenol or control for 30 min and stained for endogenous EEA1. Scale bar is 8 µm. (<bold>C</bold>) Representative western blot of a fraction isolated using antibodies to EEA1. Lanes 1–2 correspond to control HEK293 cells, lanes 3–4 to cells coexpressing Flag-AC9 and HA-β2AR, and lanes 5–6 to cells coexpressing Flag-AC1 and HA-β2AR. (<bold>D</bold>) Quantification of recovery of HA-β2AR, Flag-AC9 and Flag-AC1 in the endosome fraction relative to cell lysate. [mean ± SEM; n = 7 experiments]. **p&lt;0.01 by two-tailed t-test. (<bold>E</bold>) Representative western blot of the surface exposed fraction isolated by surface labeling with Sulfo-NHS-biotin and purified with streptavidin. Lanes 1–2 correspond to cells coexpressing Flag-AC9 and HA-β2AR, and lanes 3–4 to cells coexpressing Flag-AC1 and HA-β2AR. (<bold>F</bold>) Quantification of recovery of HA-β2AR, Flag-AC9 and Flag-AC1 in the surface biotinylated fraction relative to total cell lysate. [mean ± SEM; n = 7 experiments]. **p&lt;0.01 by two-tailed t-test. (<bold>G</bold>) Representative confocal images of HEK293 cells coexpressing HA-β2AR and Flag-AC9 after treatment with 10 µM isoproterenol or control for 30 min. Cells were treated with DMSO for 15 min prior to agonist exposure. (<bold>H</bold>) Quantification of internal puncta that are β2AR or AC9 positive, taken from wide field images (see <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D and E</xref>) [mean ± SEM; n = 3 experiments, 10 visual fields and 200+ cells per condition]. **p&lt;0.01 by two-tailed t-test. (<bold>I</bold>) Representative confocal images of HEK293 cells coexpressing HA-β2AR and Flag-AC9 after treatment with 10 µM isoproterenol or control for 30 min. Cells were treated with DYNGO-4a for 15 min prior to agonist exposure. (<bold>J</bold>) Quantification of cells with &gt;10 internal puncta that are β2AR or AC1/9 positive, taken from wide field images (see <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D and E</xref>) [mean ± SEM; n = 3 experiments, 10 visual fields and 200+ cells per condition]. **p&lt;0.01 by two-tailed t-test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58039-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Assessment of endosome fraction purity and wide field images of DYNGO-4a effect.</title><p>(<bold>A</bold>) Full western blot of the endosome fraction vs total cell lysate, probed for cellular markers Giantin (Golgi), Na/K pump (plasma membrane), calnexin (endoplasmic reticulum). Quantification of 3 such experiments. (<bold>B</bold>) uncut western blot from <xref ref-type="fig" rid="fig2">Figure 2C</xref>. (<bold>C</bold>) uncut western blot from <xref ref-type="fig" rid="fig2">Figure 2E</xref>. (<bold>D</bold>) Wide field images of HEK293 cells coexpressing HA-β2AR and Flag-AC9, pretreated with DMSO control for 15 min, after treatment with 10 µm isoproterenol or control for 30 min. Scale bar is 16 µm. (<bold>E</bold>) Wide field images of HEK293 cells coexpressing HA-β2AR and Flag-AC1, pretreated with 30 uM DYNGO-4a, after treatment with 10 µm isoproterenol or control for 30 min. Scale bar is 16 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58039-fig2-figsupp1-v2.tif"/></fig></fig-group><p>As a distinct and additional biochemical approach to verify these trafficking properties, we used cell surface biotinylation to assess protein depletion from the plasma membrane (<xref ref-type="bibr" rid="bib17">Flesch et al., 1995</xref>; <xref ref-type="bibr" rid="bib84">Whistler and von Zastrow, 1998</xref>). Isoproterenol produced a marked reduction of Flag-AC9 in the surface-biotinylated fraction but Flag-AC1 was unchanged, and surface HA-β2AR decreased after isoproterenol application irrespective of whether AC1 or AC9 was coexpressed (<xref ref-type="fig" rid="fig2">Figure 2E,F</xref>, and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). These observations independently demonstrate isoform-specific trafficking of AC9 from the plasma membrane to endosomes, regulated coordinately with endocytosis of the β2AR.</p><p>A characteristic property of the conserved, clathrin-dependent pathway mediating β2AR endocytosis is that it also requires dynamin, an endocytic GTPase which can be acutely inhibited by the cell-permeant small molecule DYNGO-4a (<xref ref-type="bibr" rid="bib30">Irannejad et al., 2013</xref>; <xref ref-type="bibr" rid="bib44">Macia et al., 2006</xref>; <xref ref-type="bibr" rid="bib47">McCluskey et al., 2013</xref>). Whereas isoproterenol promoted both Flag-β2AR and AC9-GFP to accumulate in endosomes in the vehicle (0.1% DMSO) control condition (<xref ref-type="fig" rid="fig2">Figure 2G,H</xref>, and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>), endosomal accumulation of both proteins was blocked in the presence of DYNGO-4a (<xref ref-type="fig" rid="fig2">Figure 2I and J</xref>, and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>). These results further support the hypothesis that regulated AC9 trafficking to endosomes utilizes a shared membrane pathway and mechanism relative to regulated endocytosis of the β2AR, and many other GPCRs.</p><p>Despite these similarities, AC9 and β2AR were found to traffic independently. An early clue to this distinction was that brief exposure of cells outside of the tissue culture incubator (see Materials and methods) inhibits AC9 trafficking but β2AR trafficking is resistant to this environmental stress. While we still do not fully understand the basis for this difference, it focused our attention on investigating the mechanism of AC9 traffic control in detail.</p></sec><sec id="s2-3"><title>AC9 trafficking is stimulated by GPCRs coupled to Gs but not Gi</title><p>We first asked if the β2AR is unique in its ability to stimulate endosomal accumulation of AC9 or if AC9 trafficking can be stimulated by another Gs-coupled GPCR. To do so we focused on the vasopressin-2 receptor (V2R), a Gs-coupled GPCR which also undergoes agonist-induced trafficking to early endosomes but is not endogenously expressed in HEK293 cells (<xref ref-type="bibr" rid="bib4">Birnbaumer, 2000</xref>). The V2R is of particular interest because this GPCR, unlike the β2AR, has been shown to produce a sustained cAMP response via Gs that is associated with slow recycling and binding to β-arrestin in endosomes (<xref ref-type="bibr" rid="bib29">Innamorati et al., 1998</xref>, <xref ref-type="bibr" rid="bib14">Feinstein et al., 2013</xref>; <xref ref-type="bibr" rid="bib35">Klein et al., 2001</xref>; <xref ref-type="bibr" rid="bib52">Oakley et al., 1999</xref>; <xref ref-type="bibr" rid="bib73">Thomsen et al., 2016</xref>). When examined in cells not transfected with recombinant V2Rs, Flag-AC9 remained in the plasma membrane irrespective of the presence of the V2R agonist arginine vasopressin (AVP) as expected (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). However, in cells coexpressing HA-V2R, AVP stimulated the redistribution of both Flag-AC9 and HA-V2R to a shared population of endosomes (<xref ref-type="fig" rid="fig3">Figure 3A,D,E</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>). AVP-stimulated endocytosis of both proteins was confirmed by surface biotinylation (<xref ref-type="fig" rid="fig3">Figure 3F,G</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). These results indicate that the ability of GPCR activation to promote trafficking of AC9 to endosomes is not unique to the β2AR. Rather, it appears to be a shared property of GPCRs which activate Gs.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Gs but not Gi -coupled GPCRs promote AC9 trafficking.</title><p>(<bold>A–C</bold>) Representative confocal imaging of HEK293 cells coexpressing Flag-AC9 and HA-V2R (<bold>A</bold>), HA-MOR (<bold>B</bold>), or HA-V2R-trunc (<bold>C</bold>), after treatment with 10 µM agonist (AVP or DAMGO) or control for 30 min. Scale Bar is 8 µm. (<bold>D</bold>) Quantification of internal puncta that are V2R, MOR, V2R-T, or AC1/9 positive, taken from wide field images (see <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D, E and F</xref>) [mean ± SEM; n = 3 experiments, 10 visual fields and 200+ cells per condition]. **p&lt;0.01 by two-tailed t-test. (<bold>E</bold>) Quantification of cells with &gt;10 internal puncta that are V2R, MOR, V2R-T or AC1/9 positive, taken from wide field images (see <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D, E and F</xref>) [mean ± SEM; n = 3 experiments, 10 visual fields and 200+ cells per condition]. **p&lt;0.01 by two-tailed t-test. (<bold>F</bold>) Representative western blot of the surface biotinylated fraction from HEK293 cells coexpressing HA-V2R and Flag-AC9 (lanes 1–2), HA-V2R-T and Flag-AC9 (lanes 3–4), or HA-MOR and Flag-AC9 (lanes 5–6). (<bold>G</bold>) Recovery of tagged protein in the surface biotinylated fraction relative to the total cell lysate as seen in (<bold>F</bold>) [mean ± SEM; n = 7 experiments]. **p&lt;0.01 by two-tailed t-test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58039-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Validation that V2R and V2R-T activation stimulate AC9 trafficking.</title><p>(<bold>A</bold>) Representative confocal imaging of HEK293 cells expressing Flag-AC9, after treatment with 10 µM AVP or control for 30 min. Scale Bar is 8 µm. (<bold>B</bold>) Representative western blot of the surface biotinylated fraction from HEK293 cells expressing Flag-AC9 (lanes 1–2) or coexpressing HA-V2R and Flag-AC9 (lanes 3–4) [mean ± SEM; n = 3 experiments]. (<bold>C</bold>) Uncut blot from <xref ref-type="fig" rid="fig3">Figure 3F</xref>. (<bold>D</bold>) Wide field images of HEK293 cells coexpressing HA-V2R and Flag-AC9, after treatment with 10 µm arginine vasopressin (AVP) or control for 30 min. Scale bar is 16 µm. (<bold>E</bold>) Wide field images of HEK293 cells coexpressing HA-MOR and Flag-AC9, after treatment with 10 µm [D-Ala<sup>2</sup>, N-MePhe<sup>4</sup>, Gly-ol]-enkephalin (DAMGO) or control for 30 min. Scale bar is 16 µm. (<bold>F</bold>) Wide field images of HEK293 cells coexpressing HA-V2R-trunc and Flag-AC9, after treatment with 10 µm arginine vasopressin (AVP) or control for 30 min. Scale bar is 16 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58039-fig3-figsupp1-v2.tif"/></fig></fig-group><p>We next asked if the ability to stimulate AC9 trafficking extends to GPCRs that couple to other heterotrimeric G proteins. We focused on the µ-opioid receptor (MOP-R or MOR) because this GPCR transits a similar early endocytic pathway as the β2AR (<xref ref-type="bibr" rid="bib33">Keith et al., 1998</xref>) but activates Gi rather than Gs (<xref ref-type="bibr" rid="bib34">Kieffer and Evans, 2009</xref>), and because opioid receptors have been shown explicitly to undergo ligand-dependent activation in endosomes (<xref ref-type="bibr" rid="bib64">Stoeber et al., 2018</xref>). Application of the µ-opioid agonist [D-Ala<sup>2</sup>, N-MePhe<sup>4</sup>, Gly-ol]-enkephalin (DAMGO) stimulated transfected HA-MOR to accumulate in endosomes, as shown previously, while Flag-AC9 remained in the plasma membrane (<xref ref-type="fig" rid="fig3">Figure 3B,D,E</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>). We verified selective internalization of HA-MOR, but not Flag-AC9, by surface biotinylation (<xref ref-type="fig" rid="fig3">Figure 3F,G</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>). These results suggest that the ability to stimulate AC9 trafficking to endosomes is a property specific to GPCRs which couple to Gs relative to Gi.</p><p>We then returned to the V2R, coexpressing a mutant version truncated in its C-terminal cytoplasmic tail. This mutant V2R (HA-V2R-T) retains the ability to activate Gs at the plasma membrane but internalizes less efficiently after agonist-induced activation, promotes β-arrestin recruitment to endosomes less strongly and recycles more rapidly (<xref ref-type="bibr" rid="bib29">Innamorati et al., 1998</xref>; <xref ref-type="bibr" rid="bib28">Innamorati et al., 1997</xref>; <xref ref-type="bibr" rid="bib52">Oakley et al., 1999</xref>). Despite visibly reduced internalization of HA-V2R-T after agonist application (<xref ref-type="fig" rid="fig3">Figure 3C,D,E</xref>), Flag-AC9 internalization was still observed (<xref ref-type="fig" rid="fig3">Figure 3C,D,E</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1F</xref>) and this was confirmed by surface biotinylation (<xref ref-type="fig" rid="fig3">Figure 3F,G</xref>). These results suggest that Gs-coupled GPCRs share the ability to stimulate AC9 trafficking, irrespective of differences in receptor trafficking kinetics or binding to β-arrestin in endosomes.</p></sec><sec id="s2-4"><title>AC9 trafficking is not dependent on cytoplasmic cAMP or adenylyl cyclase activity</title><p>A possible basis for such shared control of AC9 trafficking is through cAMP elevation that occurs downstream of Gs activation. To test this, we applied the diterpene drug forskolin (FSK) to stimulate cytoplasmic cAMP production independently from the receptor or Gs. While AC9 is relatively insensitive to activation by FSK, other AC isoforms that are major contributors to cAMP production in HEK293 cells (such as AC3 and AC6) are sensitive, making FSK an effective stimulus of overall cAMP elevation (<xref ref-type="bibr" rid="bib2">Baldwin et al., 2019</xref>; <xref ref-type="bibr" rid="bib60">Soto-Velasquez et al., 2018</xref>). FSK did not cause detectable internalization of either HA-β2AR or Flag-AC9 assessed by imaging (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A,C,D,I</xref>) or surface biotinylation (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E,F</xref>). Further, as expected, Flag-AC1 remained in the plasma membrane irrespective of the presence of FSK (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B–F,J</xref>). This was also true in the combined presence of 3-isobutyl-1-methylxanthine (IBMX), a phosphodiesterase inhibitor which enhances FSK-induced cAMP elevation in the cytoplasm (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1H</xref>).</p><p>As an independent approach, and to consider the possibility that cAMP exerts local rather than global control, we asked if endosomal accumulation of AC9 requires its own catalytic activity. To test this, we mutated a conserved aspartic acid residue that coordinates a catalytic magnesium in the active site, and which is essential for activity of AC6 (<xref ref-type="bibr" rid="bib18">Gao et al., 2011</xref>; <xref ref-type="bibr" rid="bib72">Tesmer, 1997</xref>). We verified that mutating the equivalent residue in AC9 (Flag-AC9-D442A) blocked cAMP production (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>), but found that regulated trafficking of Flag-AC9-D442A still occurred (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1G</xref>). Together, these results indicate that the ability of GPCR-Gs activation to regulate AC9 trafficking is not a consequence of global cytoplasmic cAMP elevation, nor does it require local cAMP production by AC9.</p></sec><sec id="s2-5"><title>Gs activation is sufficient to promote AC9 trafficking</title><p>We next investigated whether AC9 internalization is regulated by Gs itself, and did so by introducing a point mutation into the alpha subunit (HA-Gs-Q227L) that renders Gs constitutively active by reducing its rate of intrinsic GTP hydrolysis (<xref ref-type="bibr" rid="bib46">Masters et al., 1989</xref>). Flag-AC9 localized to the plasma membrane in the absence of agonist when coexpressed with wild type HA-Gs, but coexpression with activated HA-Gs-Q227L resulted in both proteins localizing to internal punctae (<xref ref-type="fig" rid="fig4">Figure 4A,C,D</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2E</xref>). This effect was specific to AC9 because AC1 remained at the plasma membrane when coexpressed with either HA-Gs or HA-Gs-Q227L (<xref ref-type="fig" rid="fig4">Figure 4B,C,D</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2F</xref>). We verified by immunoisolation that both HA-Gs-Q227L and Flag-AC9 accumulate in EEA1-positive endosomes when coexpressed (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A,B</xref>), whereas coexpression of HA-Gs-Q227L with Flag-AC1 failed to produce endosome enrichment of either protein (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2C,D</xref>). Independently supporting a discrete regulatory effect of Gs, application of cholera toxin (CTX) to activate the endogenous cellular complement of Gs resulted in receptor-independent accumulation of Flag-AC9, but not Flag-AC1, in endosomes (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Gs activation is sufficient to promote AC9 internalization.</title><p>(<bold>A</bold>) Representative confocal imaging of HEK293 cells cells coexpressing Flag-AC9, G<sub>s</sub>β, G<sub>s</sub>γ and either HA-G<sub>s</sub>α (HA-Gs) or HA-G<sub>s</sub>α-CA (HA-GsCA). (<bold>B</bold>) Representative confocal imaging of HEK293 cells coexpressing Flag-AC1, G<sub>s</sub>β, G<sub>s</sub>γ and either HA-G<sub>s</sub>α (HA-Gs) or HA-G<sub>s</sub>α-CA (HA-GsCA). (<bold>C</bold>) Quantification of internal puncta that are Gs or AC1/9 positive, taken from wide field images (see <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2C and D</xref>) [mean ± SEM; n = 3 experiments, 10 visual fields and 200+ cells per condition]. **p&lt;0.01 by two-tailed t-test. (<bold>D</bold>) Quantification of cells with &gt;10 internal puncta that are Gs or AC1/9 positive, taken from wide field images (see <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2C and D</xref>) [mean ± SEM; n = 3 experiments, 10 visual fields and 200+ cells per condition]. **p&lt;0.01 by two-tailed t-test. (<bold>E</bold>) Representative western blot of an EEA1+ fraction from HEK293 cells coexpressing Flag-AC9 and HA-Gs (lanes 1 and 3) or Flag-AC9 and HA-GsCA (lanes 2 and 4) and after treatment with 10 µM isoproterenol (lanes 1–2) or control (lanes 3–4) for 30 min. (<bold>F</bold>) Quantification of the fraction of Flag-AC9 and HA-Gs/HA-GsCA recovered in the EEA1+ fraction (<bold>E</bold>) relative to total cell lysate. [mean ± SEM; n = 3 experiments] *p&lt;0.05 **p&lt;0.01 by two-tailed t-test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58039-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Confirmation that forskolin does not promote AC9 trafficking.</title><p>(<bold>A</bold>) Representative confocal imaging of HEK293 cells coexpressing HA-β2AR and Flag-AC9 were treated with 10 µM FSK or control for 30 min. Scale Bar is 5 µm. (<bold>B</bold>) Representative confocal imaging of HEK293 cells coexpressing HA-β2AR and Flag-AC1 were treated with 10 µM FSK or control for 30 min. Scale Bar is 5 µm. (<bold>C</bold>) Quantification of internal puncta that are β2AR or AC1/9 positive, taken from wide field images (see: <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2E and F</xref> [mean ± SEM; n = 3 experiments, 10 visual fields and 200+ cells per condition]. **p&lt;0.01 by two-tailed t-test. (<bold>D</bold>) Quantification of cells with &gt;10 internal puncta that are β2AR or AC1/9 positive, taken from wide field images (see: <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2E and F</xref>) [mean ± SEM; n = 3 experiments, 10 visual fields and 200+ cells per condition]. **p&lt;0.01 by two-tailed t-test. (<bold>E</bold>) Representative western blot of the surface biotinylated fraction of cells from (<bold>A,C</bold>). (<bold>F</bold>) Quantification of the percent loss from the surface biotinylated fraction relative to the total cell lysate as seen in (<bold>E</bold>) [mean ± SEM; n = 5 experiments]. (<bold>G</bold>) Representative confocal images of HEK293 cells coexpressing HA-β2AR and the catalytic inactive mutant Flag-AC9-D442A were treated with 10 µM isoproterenol or control for 30 min. Scale Bar is 5 µm. (<bold>H</bold>) Representative confocal images of HEK293 cells coexpressing HA-β2AR and Flag-AC9 were treated with 10 µM FSK and 10 µM IBMX or control for 30 min. Scale Bar is 5 µm. (<bold>I</bold>) Representative wide-field images of HEK293 cells coexpressing HA-β2AR and Flag-AC9 which were treated with 10 µM FSK or control for 30 min. Scale Bar is 16 µm. (<bold>J</bold>) Representative wide-field images of HEK293 cells coexpressing HA-β2AR and Flag-AC1 which were treated with 10 µM FSK or control for 30 min. Scale Bar is 16 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58039-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Gs accumulation in endosomes and verification that mutational activation of Gs is sufficient to stimulate AC9 trafficking.</title><p>(<bold>A</bold>) Representative western blot of an EEA1 positive endosome fraction from HEK293 cells coexpressing Flag-AC9, G<sub>s</sub>β, G<sub>s</sub>γ and HA-Gs (lane 1) or HA-GsCA (lane 2). (<bold>B</bold>) Quantification of endosome enrichment of Flag-AC9 and HA-Gs or HA-GsCA as seen in (<bold>A</bold>) by normalizing to the EEA1 signal. [mean ± SEM; n = 5 experiments] **p&lt;0.01 by two-tailed t-test. (<bold>C</bold>) Representative western blot of an EEA1 positive endosome fraction from HEK293 cells coexpressing Flag-AC1, G<sub>s</sub>β, G<sub>s</sub>γ and HA-Gs (Gs, lane 1) or HA-Gs-Q227L (GsCA, lane 2). (<bold>D</bold>) Quantification of endosome enrichment of Flag-AC1 and HA-Gs or HA-GsCA as seen in (<bold>B</bold>) by normalizing to the EEA1 signal. [mean ± SEM; n = 5 experiments] **p&lt;0.01 by two-tailed t-test. (<bold>E</bold>) Representative wide-field images of HEK293 cells coexpressing HA-Gs (wild type) or HA-Gs-Q227L and Flag-AC9. Scale Bar is 16 µm. (<bold>F</bold>) Representative wide-field images of HEK293 cells coexpressing HA-Gs (wild type) or HA-Gs-Q227L and Flag-AC1. Scale Bar is 16 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58039-fig4-figsupp2-v2.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Effect of cholera toxin on AC9 trafficking.</title><p>(<bold>A</bold>) Representative confocal images of HEK293 cells coexpressing HA-β2AR and Flag-AC9 were treated with 100 nM cholera toxin overnight. Scale Bar is 8 µm. (<bold>B</bold>) Representative confocal images of HEK293 cells coexpressing HA-β2AR and Flag-AC1 were treated with 100 nM cholera toxin overnight. (<bold>C</bold>) Representative wide-field images of HEK293 cells coexpressing HA-β2AR and Flag-AC9 were treated with 100 nM cholera toxin overnight. Scale Bar is 8 µm. (<bold>D</bold>) Representative wide-field images of HEK293 cells coexpressing HA-β2AR and Flag-AC1 were treated with 100 nM cholera toxin overnight.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58039-fig4-figsupp3-v2.tif"/></fig></fig-group><p>The immunoisolation analysis also indicated that constitutive activation of Gs produced a degree of endosomal enrichment of AC9 similar to that produced in response to endogenous β2AR activation with isoproterenol. Further, application of isoproterenol to cells which coexpress HA-Gs-Q227L did not detectably increase the degree of endosomal enrichment observed for either Gs or AC9 (<xref ref-type="fig" rid="fig4">Figure 4E,F</xref>). Together, these results suggest that Gs activation mediated by endogenous β2ARs is fully sufficient to stimulate AC9 trafficking to endosomes, without requiring additional effects of upstream receptor activation or downstream cAMP signaling.</p></sec><sec id="s2-6"><title>Regulation of AC9 trafficking requires Gs but not β-arrestin</title><p>Because Gs activation is sufficient to stimulate accumulation of AC9 in endosomes, we next asked if it is necessary to regulate this trafficking process. To do so, we utilized previously described Gs-knockout (GsKO) cells which lack Gs due to CRISPR-mediated editing of the alpha subunit (GNAS) gene (<xref ref-type="bibr" rid="bib63">Stallaert et al., 2017</xref>). Flag-β2AR and AC9-EGFP localized to the plasma membrane of GsKO as well as wild type HEK293 cells. However, AC9-GFP internalization was blocked in GsKO cells while Flag-β2AR still internalized. Moreover, AC9 trafficking was rescued by expression of recombinant HA-Gs (<xref ref-type="fig" rid="fig5">Figure 5A-D</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A,B</xref>). These results indicate that Gs is necessary for regulated trafficking of AC9 but not β2AR.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Regulation of AC9 internalization requires Gs but not beta-arrestin.</title><p>(<bold>A–B</bold>) Representative confocal imaging of Gs-knockout (GsKO) HEK293 cells coexpressing Flag-β2AR, AC9-EGFP, and either pcDNA3 (<bold>A</bold>) or wild-type HA-Gs rescue (<bold>B</bold>). (<bold>C–D</bold>) Representative confocal imaging of Arrestin2/3 (β-arrestin −1 and 2) double knockout (Arr DKO) cells coexpressing Flag-β2AR, AC9-EGFP, and either pcDNA3 (<bold>C</bold>) or HA-Arrestin three rescue (<bold>D</bold>). (<bold>E</bold>) Quantification of internal puncta that are β2AR or AC9 positive, taken from wide field images (see <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A and B</xref>) [mean ± SEM; n = 3 experiments, 10 visual fields and 200+ cells per condition]. **p&lt;0.01 by two-tailed t-test. (<bold>F</bold>) Quantification of cells with &gt;10 internal puncta that are β2AR or AC9 positive, taken from wide field images (see <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A and B</xref>) [mean ± SEM; n = 3 experiments, 10 visual fields and 200+ cells per condition]. **p&lt;0.01 by two-tailed t-test. (<bold>G</bold>) Quantification of internal puncta that are β2AR or AC9 positive, taken from wide field images (see <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C and D</xref>) [mean ± SEM; n = 3 experiments, 10 visual fields and 200+ cells per condition]. **p&lt;0.01 by two-tailed t-test. (<bold>H</bold>) Quantification of cells with &gt;10 internal puncta that are Gs or AC1/9 positive, taken from wide field images (see <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C and D</xref>) [mean ± SEM; n = 3 experiments, 10 visual fields and 200+ cells per condition]. **p&lt;0.01 by two-tailed t-test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58039-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Wide field images supporting distinct trafficking effects of Gs KO and Arr DKO.</title><p>(<bold>A</bold>) Representative wide-field images of Gs-knockout HEK293 cells coexpressing HA-β2AR and Flag-AC9 were treated with 10 µM isoproterenol for 30 min. Scale Bar is 16 µm. (<bold>B</bold>) Representative wide-field images of Gs-knockout HEK293 cells coexpressing Gs (wild type) HA-β2AR and Flag-AC9 were treated with 10 µM isoproterenol for 30 min. Scale Bar is 16 µm. (<bold>C</bold>) Representative wide-field images of Arrestin 2/3 double knockout HEK293 cells coexpressing HA-β2AR and Flag-AC9 were treated with 10 µM isoproterenol for 30 min. Scale Bar is 16 µm. (<bold>D</bold>) Representative wide-field images of Arrestin 2/3 double knockout HEK293 cells coexpressing Arrestin 2, HA-β2AR and Flag-AC9 were treated with 10 µM isoproterenol for 30 min. Scale Bar is 16 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58039-fig5-figsupp1-v2.tif"/></fig></fig-group><p>Stimulation of β2AR endocytosis by agonists is known to depend on β-arrestins (<xref ref-type="bibr" rid="bib15">Ferguson et al., 1996</xref>; <xref ref-type="bibr" rid="bib21">Goodman et al., 1996</xref>). Accordingly, we asked if this is also true for AC9. To test this, we used gene-edited HEK293 cells lacking both β-arrestin isoforms (Arrestins 2 and 3, or β-arrestin-1 and β-arrestin-2) (<xref ref-type="bibr" rid="bib51">O'Hayre et al., 2017</xref>). Isoproterenol-stimulated internalization of HA-β2AR was lost in β-arrestin double-knockout (Arr DKO) cells, as expected, but AC9-EGFP internalization was still observed. Further, expressing recombinant Arrestin 3 (β-arrestin-2) rescued the HA-β2AR trafficking defect without a noticeable change in AC9-EGFP trafficking (<xref ref-type="fig" rid="fig5">Figure 5E-H</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C,D</xref>). These results indicate that AC9 and GPCR trafficking are regulated coordinately but through distinct mechanisms– with AC9 requiring Gs but not β-arrestin, and the GPCR requiring β-arrestin but not Gs.</p></sec><sec id="s2-7"><title>Functional evidence for AC9 signaling from endosomes</title><p>Both AC1 and AC9 are known physiological effectors of β-adrenergic signaling (<xref ref-type="bibr" rid="bib57">Sadana and Dessauer, 2009</xref>; <xref ref-type="bibr" rid="bib59">Small et al., 2003</xref>; <xref ref-type="bibr" rid="bib69">Tantisira et al., 2005</xref>) and both are endogenously expressed in HEK293 cells, despite neither being the primary contributor to global cAMP elevation produced by β2AR activation in this cell type. Nevertheless, analysis by isoform-specific knockdown using siRNA indicated that both AC1 and AC9 make a small but statistically significant contribution to the overall cAMP elevation elicited by activation of endogenous β2ARs. AC1 but not AC9 depletion reduced the FSK-induced cAMP response (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>), consistent with AC9 being relatively insensitive to stimulation by FSK (<xref ref-type="bibr" rid="bib2">Baldwin et al., 2019</xref>) and verifying specificity of the knockdown approach. Considering that AC9 selectively accumulates in endosomes relative to AC1, we next investigated the hypothesis that AC9 also selectively contributes to the endosome-initiated component of the β2AR-elicited cellular cAMP response.</p><p>We tested this hypothesis using a pharmacological approach based on the ability of the membrane-impermeant β2AR antagonist CGP12177 (CGP) to access receptors selectively at the plasma membrane, whereas the membrane-permeant antagonist alprenolol accesses receptors both at the plasma membrane and endosomes (<xref ref-type="bibr" rid="bib62">Staehelin et al., 1983</xref>). This approach has been used successfully in previous studies to isolate effects of endosomal activation (<xref ref-type="bibr" rid="bib30">Irannejad et al., 2013</xref>; <xref ref-type="bibr" rid="bib73">Thomsen et al., 2016</xref>). We validated it in the present study using a conformational biosensor, Nb80-EGFP, which is recruited specifically and reversibly by activated β2ARs in living cells (<xref ref-type="bibr" rid="bib30">Irannejad et al., 2013</xref>). Isoproterenol application promoted recruitment of Nb80-GFP both to the plasma membrane and endosomes, and application of excess alprenolol rapidly reversed this activation readout at both locations (<xref ref-type="fig" rid="fig6">Figure 6A</xref>, <xref ref-type="video" rid="video2">Video 2</xref>). Application of CGP, in contrast, reversed Nb80-GFP recruitment only at the plasma membrane but not endosomes (<xref ref-type="fig" rid="fig6">Figure 6B</xref>, <xref ref-type="video" rid="video3">Video 3</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>AC9 selectively contributes to the β2AR-mediated cAMP response from endosomes.</title><p>(<bold>A</bold>) Recruitment of conformational biosensors to β2AR-containing endosomes is reversed by application of the membrane permeable antagonist alprenolol for 20 min. Scale Bar is 8 µm. See <xref ref-type="video" rid="video2">Video 2</xref> for full image series. (<bold>B</bold>) Recruitment of conformational biosensors to β2AR-containing endosomes is unaffected by application of the membrane impermeable antagonist CGP12177 for 20 min. Scale Bar is 8 µm. See <xref ref-type="video" rid="video3">Video 3</xref> for full image series. (<bold>C</bold>) Quantification of the maximum cAMP response in control and in AC9 siRNA knockdown HEK293 cells pretreated with 100 nM isoproterenol and exposed to supersaturating conditions of membrane permeable antagonist (10 µM alprenolol) or membrane impermeable antagonist (10 µM CGP12177). [mean ± SEM; n = 4 experiments] (<bold>D</bold>) Quantification of the maximum cAMP response in control in AC1 siRNA knockdown HEK293 cells pretreated with 100 nM isoproterenol and exposed to supersaturating conditions of membrane permeable antagonist (10 µM alprenolol) or membrane impermeable antagonist (10 µM CGP12177). [mean ± SEM; n = 4 experiments] (<bold>E</bold>) Quantification of the maximum cAMP response in AC3/6KO HEK293 cells due to AC9 overexpression as the delta between the Flag-AC9 and pcDNA3 conditions. Cells were pretreated with 100 nM isoproterenol and exposed to supersaturating conditions of membrane permeable antagonist (10 µM alprenolol) or membrane impermeable antagonist (10 µM CGP12177). [mean ± SEM; n = 4 experiments] (<bold>F</bold>) Quantification of the maximum cAMP response in AC3/6KO HEK293 cells due to AC1 overexpression as the delta between the Flag-AC1 and pcDNA3 conditions. Cells were pretreated with 100 nM isoproterenol and exposed to supersaturating conditions of membrane permeable antagonist (10 µM alprenolol) or membrane impermeable antagonist (10 µM CGP12177). [mean ± SEM; n = 4 experiments] (<bold>G</bold>) Model: Ligand binding causes initial signaling event at the PM followed by arrestin-dependent endocytosis of β2AR. AC1 is restricted to the PM but AC9 is dynamically redistributed by a distinct Gs regulated process, and contributes to the β2AR-mediated cAMP response from the endosome.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58039-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Verification that AC9 selectively contributes to cAMP production stimulated by endogenous receptor activation in endosomes.</title><p>(<bold>A</bold>) Percent knockdown of AC9 and AC1 in HEK293 cells as determined by qPCR. [mean ± SEM; n = 3 experiments] (<bold>B</bold>) Effect of siRNA knockdown of AC9 and AC1 expression in HEK293 cells on the cAMP response to 10 µM FSK and 10 µM isoproterenol stimulation [mean ± SEM; n = 4 experiments] *p&lt;0.05 by two-tailed t-test. (<bold>C</bold>) Representative cAMP response to 10 µM FSK or 10 µM isoproterenol under conditions of siRNA knockdown of AC1 expression or control (ASD). (<bold>D</bold>) Quantification of the maximum cAMP response as seen in (<bold>C</bold>) [mean ± SEM; n = 3 experiments]. (<bold>E</bold>) Representative normalized β2AR-mediated cAMP response in control HEK293 cells pretreated with 100 nM isoproterenol and exposed to supersaturating antagonist conditions (10 µM CGP12177, 10 µM alprenolol). (<bold>F</bold>) Representative normalized β2AR-mediated cAMP response in AC1 knockdown HEK293 cells pretreated with 100 nM isoproterenol and exposed to supersaturating antagonist conditions (10 µM CGP12177, 10 µM alprenolol). (<bold>G</bold>) Representative normalized β2AR-mediated cAMP response in control HEK293 cells pretreated with 100 nM isoproterenol and exposed to supersaturating antagonist conditions (10 µM CGP12177, 10 µM alprenolol). (<bold>H</bold>) Representative normalized β2AR-mediated cAMP response in AC9 knockdown HEK293 cells pretreated with 100 nM isoproterenol and exposed to supersaturating antagonist conditions (10 µM CGP12177, 10 µM alprenolol).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58039-fig6-figsupp1-v2.tif"/></fig></fig-group><media id="video2" mime-subtype="mp4" mimetype="video" xlink:href="elife-58039-video2.mp4"><label>Video 2.</label><caption><title>This movie shows a confocal image series of β2AR (red) and Nb80-EGFP (green) from a HEK293 cell pre-incubated for 20 min with 100 nM isoproterenol.</title><p>10 µM alprenolol, added at t = 0 time point indicated in the time stamp, reverses Nb80-EGFP recruitment to β2ARs at both the plasma membrane and endosomes.</p></caption></media><media id="video3" mime-subtype="mp4" mimetype="video" xlink:href="elife-58039-video3.mp4"><label>Video 3.</label><caption><title>This movie shows a confocal image series of β2AR (red) and Nb80-EGFP (green) from a HEK293 cell pre-incubated for 20 min with 100 nM isoproterenol.</title><p>10 µM CGP12177, added at t = 0 indicated in the time stamp, reverses Nb80-EGFP recruitment to β2ARs at the plasma membrane but not at endosomes.</p></caption></media><p>We next applied this approach to probe the contribution of endosomal β2AR activation to the overall cellular cytoplasmic cAMP response. Both CGP and alprenolol markedly inhibited the isoproterenol-induced cAMP elevation measured at 37 °C in living cells. This verifies that a large fraction of the overall cAMP elevation elicited by endogenous β2AR activation in these cells is initiated from the plasma membrane. However, we also consistently observed a more pronounced inhibition of cellular cAMP elevation following application of alprenolol compared to CGP (<xref ref-type="fig" rid="fig6">Figure 6C</xref>, left set of bars, and <xref ref-type="video" rid="video4">Video 4</xref>). We interpret this difference as a readout of the component of cAMP production initiated from endosomes. Remarkably, this CGP-resistant ‘signal gap’ was lost after AC9 knockdown but it remained in cells depleted of AC1 (<xref ref-type="fig" rid="fig6">Figure 6C,D</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C–H</xref>).</p><media id="video4" mime-subtype="mp4" mimetype="video" xlink:href="elife-58039-video4.mp4"><label>Video 4.</label><caption><title>This movie shows an image series of the luminescence-based cAMP biosensor from HEK293 cells that have been treated with control siRNA (columns 1 and 2) or AC9 siRNA (columns 3 and 4).</title><p>Cells were preincubated with 100 nM isoproterenol for 20 min prior to imaging, and 10 µM CGP12177 or 10 µM alprenolol were added immediately before imaging, where indicated.</p></caption></media><p>As another test of this hypothesis, and to investigate selectivity under conditions of recombinant AC overexpression (which were necessary for the trafficking studies), we asked if similar selectivity can be observed also using tagged AC isoforms. To do so we utilized gene-edited HEK293 cells lacking both AC3 and AC6 (AC3/6 DKO), which were shown previously to provide a reduced background useful for assessing effects of recombinant AC expression on cellular cAMP (<xref ref-type="bibr" rid="bib60">Soto-Velasquez et al., 2018</xref>). The increment of isoproterenol-induced cAMP accumulation produced by overexpressing Flag-AC9 in these cells (‘AC9 cAMP response’) was blocked by alprenolol but not CGP (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). In contrast, the corresponding increment produced by overexpressing Flag-AC1 (‘AC1 cAMP response’) was blocked by both alprenolol and CGP (<xref ref-type="fig" rid="fig6">Figure 6F</xref>). This verifies that AC9 selectively contributes to cellular cAMP production initiated by β2AR activation in endosomes using recombinant, as well as endogenous AC9.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The endocytic network is a dynamically regulated system critical for homeostatic integrity of the cell. From the point of view of GPCR-G protein signaling, this network was believed for many years to be silent, functioning only in signal termination and longer-term modulation of surface receptor number. Such homeostatic effects indeed occur, but an accumulating body of evidence supports an expanded view in which internalized GPCRs reacquire the ability to activate G proteins after endocytosis and initiate a second wave of signaling from endomembrane sites (<xref ref-type="bibr" rid="bib31">Irannejad et al., 2015</xref>; <xref ref-type="bibr" rid="bib42">Lohse and Calebiro, 2013</xref>; <xref ref-type="bibr" rid="bib78">Vilardaga et al., 2014</xref>). Endosomal signaling depends on the presence of a G protein-regulated effector, but whether or how effectors localize to relevant internal membrane locations has remained a relatively unexplored frontier.</p><p>We approached this frontier by focusing on ACs as important effectors of signaling initiated by GPCR - Gs activation. We demonstrate dynamic and regulated trafficking of AC9 to early endosomes. This compartment is known to accumulate a wide variety of GPCRs, and it has been explicitly shown to be a site of Gs activation by the β2AR (<xref ref-type="bibr" rid="bib30">Irannejad et al., 2013</xref>). AC9 is widely expressed (<xref ref-type="bibr" rid="bib54">Premont et al., 1996</xref>), is a physiologically and clinically relevant effector of β2AR-Gs signaling in particular (<xref ref-type="bibr" rid="bib59">Small et al., 2003</xref>; <xref ref-type="bibr" rid="bib66">Sunahara et al., 1996</xref>; <xref ref-type="bibr" rid="bib69">Tantisira et al., 2005</xref>) and is endogenously expressed in the HEK293 model system used in the present study. We also show that AC9, while contributing only a minor fraction to the overall cellular cAMP response elicited by β2AR activation in this system, is necessary to produce a specific endosome-initiated component of the endogenous β2AR-elicited cAMP response. Further, we demonstrate that AC9 is sufficient to increase cAMP production from endosomes when expressed as a recombinant protein. Moreover, we show that AC trafficking is isoform-specific because AC1 does not detectably accumulate in endosomes, nor does AC1 contribute detectably to the endosome-initiated component of cellular cAMP signaling (<xref ref-type="fig" rid="fig6">Figure 6G</xref>).</p><p>An important future goal is to identify structural and biochemical determinants of isoform-specific AC trafficking. We note that various isoform-specific protein interactions which impact other aspects of AC organization and function are already known, with AC9 being a particularly well-studied example (<xref ref-type="bibr" rid="bib2">Baldwin et al., 2019</xref>). Another important question for future investigation is whether regulated intracellular trafficking is unique to AC9 or more widespread. We favor the latter possibility because a distantly related AC isoform was previously localized to a multivesicular intracellular compartment in <italic>D. discoideum</italic> (<xref ref-type="bibr" rid="bib37">Kriebel et al., 2008</xref>). However, in this case, AC trafficking appears to occur through the biosynthetic pathway and it is not known if the AC-containing compartment also contains a relevant GPCR or G protein. We also note that several other transmembrane AC isoforms have been implicated previously in endomembrane cAMP signaling by mammalian GPCRs (<xref ref-type="bibr" rid="bib5">Calebiro et al., 2009</xref>; <xref ref-type="bibr" rid="bib6">Cancino et al., 2014</xref>; <xref ref-type="bibr" rid="bib16">Ferrandon et al., 2009</xref>; <xref ref-type="bibr" rid="bib36">Kotowski et al., 2011</xref>; <xref ref-type="bibr" rid="bib48">Mullershausen et al., 2009</xref>; <xref ref-type="bibr" rid="bib78">Vilardaga et al., 2014</xref>), and that a distinct AC isoform which lacks any transmembrane domains (‘soluble’ AC or AC10) has been implicated as well (<xref ref-type="bibr" rid="bib27">Inda et al., 2016</xref>). Thus we anticipate that AC9 is not the only isoform to exhibit discrete trafficking behavior, and that much remains to be learned along this line. In particular, we note that the localization and trafficking properties of AC3 and AC6– which are major contributors to overall cAMP production stimulated by β2ARs in HEK293 cells (<xref ref-type="bibr" rid="bib60">Soto-Velasquez et al., 2018</xref>)– have yet to be delineated.</p><p>One possible mechanism of AC9 trafficking to GPCR-containing endosomes is by physical association with the receptor or receptor-G protein complex, and there is previous evidence indicating that AC5 can form a complex including GPCRs (<xref ref-type="bibr" rid="bib49">Navarro et al., 2018</xref>). However, our results provide two lines of evidence indicating that AC9 traffics independently, despite trafficking via a similar dynamin-dependent membrane pathway as the β2AR and in a coordinated manner. First, activation of Gs is sufficient to promote the accumulation of AC9 but not β2AR in endosomes. Second, AC9 trafficking requires Gs but not β-arrestins, whereas the converse is true for trafficking of the β2AR. Accordingly, AC trafficking is likely subject to different modulatory input(s) relative to the trafficking of GPCRs. This is consistent with the difference in environmental sensitivity between AC9 and β2AR trafficking which initially motivated our investigations. However, additional studies will be required to fully elucidate the mechanistic basis for differential control of AC9 trafficking, and to delineate physiological inputs into regulated AC trafficking more broadly. The physiological significance of isoform-specific AC trafficking also remains to be determined, but we note that there is already significant evidence that cAMP produced internally can mediate different downstream signaling effects relative to cAMP produced from the plasma membrane (<xref ref-type="bibr" rid="bib50">O'Banion et al., 2019</xref>; <xref ref-type="bibr" rid="bib76">Tsvetanova and von Zastrow, 2014</xref>).</p><p>In closing, to our knowledge the present study is the first to delineate the dynamic endocytic trafficking of a functionally relevant AC isoform, and to identify a role of Gs in regulating the trafficking of a defined AC separately from its catalytic activity. The finding that such AC trafficking is isoform-specific, and regulated separately from its activating GPCR, reveals a new layer of specificity and control in the cAMP system.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type <break/>(species) or resource</th><th valign="top">Designation</th><th valign="top">Source or reference</th><th valign="top">Identifiers</th><th valign="top">Additional information</th></tr></thead><tbody><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">HEK293</td><td valign="top">ATCC</td><td valign="top">CRL-1573; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_0045">CVCL_0045</ext-link></td><td valign="top">Human embryonic kidney (female)</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">GNAS-knockout</td><td valign="top"><xref ref-type="bibr" rid="bib63">Stallaert et al., 2017</xref></td><td valign="top"/><td valign="top">HEK293 parental</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Arrestin 2 and 3 double knockout</td><td valign="top"><xref ref-type="bibr" rid="bib51">O'Hayre et al., 2017</xref></td><td valign="top"/><td valign="top">HEK293 parental</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">ADCY 3 and 6 double knockout</td><td valign="top"><xref ref-type="bibr" rid="bib60">Soto-Velasquez et al., 2018</xref></td><td valign="top"/><td valign="top">HEK293 parental</td></tr><tr><td valign="top">Biological sample (<italic>Homo sapiens</italic>)</td><td valign="top">Human smooth airway muscle cells (HSAMs)</td><td valign="top">Prepared from lung biopsy (<xref ref-type="bibr" rid="bib75">Tsvetanova et al., 2017</xref>)</td><td valign="top"/><td valign="top">Primary cell culture</td></tr><tr><td valign="top">Antibody</td><td valign="top">Mouse anti-FLAG (M1)</td><td valign="top">Sigma-Aldrich</td><td valign="top">F-3040; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_439712">AB_439712</ext-link></td><td valign="top">(1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit anti-Flag</td><td valign="top">Sigma-Aldrich</td><td valign="top">F7425; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_439687">AB_439687</ext-link></td><td valign="top">(1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Mouse anti-HA</td><td valign="top">Biolegend</td><td valign="top">16B12; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2820200">AB_2820200</ext-link></td><td valign="top">(1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Goat anti-AC9</td><td valign="top">Santa Cruz Biotech</td><td valign="top">sc-8576; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2223286">AB_2223286</ext-link></td><td valign="top">(1:50)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Mouse anti-EEA1</td><td valign="top">Fisher Scientific</td><td valign="top">610457; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_397830">AB_397830</ext-link></td><td valign="top">(1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Mouse anti-Golgin-97</td><td valign="top">Thermo</td><td valign="top">A-21270; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_221447">AB_221447</ext-link></td><td valign="top">(1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit anti-calnexin</td><td valign="top">Cell Signaling</td><td valign="top">2679P; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2228381">AB_2228381</ext-link></td><td valign="top">(1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Mouse anti-Sodium/Potassium ATPase</td><td valign="top">Novus Biologicals</td><td valign="top">NB300-540SS; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_306023">AB_306023</ext-link></td><td valign="top">(1:1000)</td></tr><tr><td valign="top">Recombinant DNA reagent (human)</td><td valign="top">Flag-AC9 (plasmid)</td><td valign="top"><xref ref-type="bibr" rid="bib53">Paterson et al., 2000</xref></td><td valign="top"/><td valign="top">pcDNA3 backbone</td></tr><tr><td valign="top">Recombinant DNA reagent (human)</td><td valign="top">Flag-AC1</td><td valign="top"><xref ref-type="bibr" rid="bib8">Chen et al., 1997</xref></td><td valign="top"/><td valign="top">pcDNA3 backbone</td></tr><tr><td valign="top">Recombinant DNA reagent (human)</td><td valign="top">Flag-AC9-D442A</td><td valign="top">This study</td><td valign="top"/><td valign="top">pcDNA3 backbone</td></tr><tr><td valign="top">Recombinant DNA reagent (human)</td><td valign="top">AC9-EGFP</td><td valign="top">This study</td><td valign="top"/><td valign="top">EGFP-C1 backbone</td></tr><tr><td valign="top">Recombinant DNA reagent (human)</td><td valign="top">HA-B2AR</td><td valign="top"><xref ref-type="bibr" rid="bib80">von Zastrow and Kobilka, 1992</xref></td><td valign="top"/><td valign="top">pcDNA3 backbone</td></tr><tr><td valign="top">Recombinant DNA reagent (human)</td><td valign="top">HA-V2R</td><td valign="top"><xref ref-type="bibr" rid="bib55">Rochdi et al., 2010</xref></td><td valign="top"/><td valign="top">pcDNA3 backbone</td></tr><tr><td valign="top">Recombinant DNA reagent (mouse)</td><td valign="top">HA-MOR</td><td valign="top"><xref ref-type="bibr" rid="bib84">Whistler and von Zastrow, 1998</xref></td><td valign="top"/><td valign="top">pcDNA3 backbone</td></tr><tr><td valign="top">Recombinant DNA reagent (human)</td><td valign="top">HA-V2R-T</td><td valign="top"><xref ref-type="bibr" rid="bib55">Rochdi et al., 2010</xref></td><td valign="top"/><td valign="top">pcDNA3 backbone</td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">Nb80-EGFP</td><td valign="top"><xref ref-type="bibr" rid="bib30">Irannejad et al., 2013</xref></td><td valign="top"/><td valign="top">EGFP-C1 backbone</td></tr><tr><td valign="top">Recombinant DNA reagent (human)</td><td valign="top">HA-G(alpha)s</td><td valign="top"><xref ref-type="bibr" rid="bib30">Irannejad et al., 2013</xref></td><td valign="top"/><td valign="top">pcDNA3 backbone</td></tr><tr><td valign="top">Recombinant DNA reagent (human)</td><td valign="top">G(beta-1)</td><td valign="top"><xref ref-type="bibr" rid="bib30">Irannejad et al., 2013</xref></td><td valign="top"/><td valign="top">pcDNA3 backbone</td></tr><tr><td valign="top">Recombinant DNA reagent (human)</td><td valign="top">G(gamma-2)</td><td valign="top"><xref ref-type="bibr" rid="bib30">Irannejad et al., 2013</xref></td><td valign="top"/><td valign="top">pcDNA3 backbone</td></tr><tr><td valign="top">Recombinant DNA reagent (human)</td><td valign="top">HA-G(alpha)s-Q227L</td><td valign="top"><xref ref-type="bibr" rid="bib46">Masters et al., 1989</xref></td><td valign="top"/><td valign="top">pcDNA3 backbone</td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pGloSensor-20F</td><td valign="top">Promega</td><td valign="top">E1171</td><td valign="top"/></tr><tr><td valign="top">Transfected construct (human)</td><td valign="top">AC9-siRNA</td><td valign="top">This study</td><td valign="top"/><td valign="top">See Materials and methods for sequence</td></tr><tr><td valign="top">Transfected construct (human)</td><td valign="top">AC1 siRNA</td><td valign="top">This study</td><td valign="top"/><td valign="top">See Materials and methods for sequence</td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Isoprenaline (iso)</td><td valign="top">Sigma-Aldrich</td><td valign="top">51-30-9</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Arginine-vasopressin (AVP)</td><td valign="top">Sigma-Aldrich</td><td valign="top">113-79-1</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">DAMGO, [D-Ala2, N-Me-Phe4, Gly5-ol]-Enkephalin acetate salt</td><td valign="top">Sigma-Aldrich</td><td valign="top">E7384</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">DYNGO-4a</td><td valign="top">Abcam Biochemicals</td><td valign="top">ab120689</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Alprenolol</td><td valign="top">Sigma</td><td valign="top">3707-88-5</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">CGP12177</td><td valign="top">Tocris</td><td valign="top">1134</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Forskolin</td><td valign="top">Sigma-Aldrich</td><td valign="top">66575-29-9</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">3-isobutyl-1-methylxanthine (IBMX)</td><td valign="top">Sigma-Aldrich</td><td valign="top">28822-58-4</td><td valign="top"/></tr><tr><td valign="top">Chemical compound</td><td valign="top">D-Luciferin, sodium salt</td><td valign="top">Gold Biosciences</td><td valign="top">LUCNA-1G</td><td valign="top"/></tr><tr><td valign="top">Chemical compound</td><td valign="top">Anti-mouse IgG Magnetic microbeads</td><td valign="top">Miltenyi</td><td valign="top">130-047-101</td><td valign="top"/></tr><tr><td valign="top">Chemical compound</td><td valign="top">EZ-link Sulfo-NHS-biotin</td><td valign="top">Pierce</td><td valign="top">21425</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Alexa Fluor 647 Protein Labeling Kit</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">A20173</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Alexa Fluor 488 Protein Labeling Kit</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">A20181</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Direct cAMP ELISA</td><td valign="top">Enzo Life Sciences</td><td valign="top">ADI-900–066</td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Prism</td><td valign="top">GraphPad</td><td valign="top">8.1.1</td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">ImageJ</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://Imagej.net">Imagej.net</ext-link></td><td valign="top">2.0.0-rc-69/1.52 p</td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">MATLAB</td><td valign="top">MathWorks</td><td valign="top">R2014b</td><td valign="top"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Cell culture, expression constructs, and transfections</title><p>HEK 293 cells (CRL-1573, ATCC, mycoplasma-tested) were cultured in complete growth Dulbecco’s modified Eagle’s medium (DMEM, Gibco) and supplemented with 10% fetal bovine serum (UCSF Cell Culture Facility). HA-β2AR (<xref ref-type="bibr" rid="bib68">Tang et al., 1999</xref>; <xref ref-type="bibr" rid="bib80">von Zastrow and Kobilka, 1992</xref>), HA-V2R (<xref ref-type="bibr" rid="bib55">Rochdi et al., 2010</xref>), HA-MOR (<xref ref-type="bibr" rid="bib84">Whistler and von Zastrow, 1998</xref>), HA-V2R-T (<xref ref-type="bibr" rid="bib7">Charest and Bouvier, 2003</xref>; <xref ref-type="bibr" rid="bib55">Rochdi et al., 2010</xref>), all described previously, were sub-cloned from Flag-tagged constructs. Nb80-EGFP was previously described (<xref ref-type="bibr" rid="bib30">Irannejad et al., 2013</xref>). HA-G(alpha)s, G(beta-1), G(gamma-2) were gifts from Philip Wedegaertner. HA-G(alpha)s-Q227L, a previously described point mutant of Gs that is constitutively active (<xref ref-type="bibr" rid="bib46">Masters et al., 1989</xref>), was made from the original construct using the QuikChange Site-Directed Mutagenesis Kit (Agilent Technologies) with the forward primer 5’-<named-content content-type="sequence">CGATGTGGGCGGCCTGCGCGATGAACGCCGC</named-content>-3’. Flag-AC1, Flag-AC9 from the Dessauer Lab, were originally described by <xref ref-type="bibr" rid="bib22">Hacker et al., 1998</xref>; <xref ref-type="bibr" rid="bib38">Krupinski et al., 1989</xref>; <xref ref-type="bibr" rid="bib53">Paterson et al., 2000</xref>; <xref ref-type="bibr" rid="bib54">Premont et al., 1996</xref>. Flag-AC9-D442A (Catalytic inactive mutant) was also made from the original construct using QuikChange Kit with the forward primer 5’-<named-content content-type="sequence">CCACTAGTCCAGTGTGGTGGAATTCGCCATGGACTACAAAGACGATGACGAC</named-content>-3’. Transfections were carried out using Lipofectamine 2000 (Life Technologies) according to the manufacturer’s protocol. Cells were transfected 48 hr before experiments. siRNA knockdown of AC1 and AC9 expression in HEK293 cells was carried out using Lipofectamine RNAiMAX (Life Technologies) according to the manufacturer’s protocol. Cells were transfected 72 hr before experiments. Knockdown of AC1 used the siRNA <named-content content-type="sequence">CCGGGCGGTTCAGACCTTCAA</named-content> and AC9 knockdown used <named-content content-type="sequence">CTGGGCATGAGGAGGTTTAAA</named-content>.</p><p>Primary cultures of human airway smooth muscle cells were prepared as described previously (<xref ref-type="bibr" rid="bib75">Tsvetanova et al., 2017</xref>). Cells were passaged no more than five times using Trypsin-EDTA (Life Technologies) and maintained in 10% FBS in DMEM.</p><p>Gs knockout (<xref ref-type="bibr" rid="bib63">Stallaert et al., 2017</xref>) and beta-arrestin-1/2 double knockout (<xref ref-type="bibr" rid="bib51">O'Hayre et al., 2017</xref>) HEK293 cells were previously described. AC3/AC6 double knockout HEK293 cells were also described previously (<xref ref-type="bibr" rid="bib60">Soto-Velasquez et al., 2018</xref>) and were provided as a generous gift by Drs. Monica Soto-Valasquez and Val Watts (Purdue University). Cells were passaged using PBS-EDTA and maintained in 10% FBS in DMEM.</p><p>Cholera Toxin (Sigma) was administered to cells for 16 hr overnight treatment at 10 ng/ml concentration in 10% FBS in DMEM.</p><p>We found AC9 trafficking to be environmentally sensitive. Specifically, exposure of cells outside of the incubator for more than 2 min tended to reduce the degree of isoproterenol-stimulated internalization of AC9, without affecting internalization of β2AR. Accordingly, this restriction was consistently adhered to in the present study.</p></sec><sec id="s4-2"><title>Antibodies</title><p>Antibodies used were rabbit anti-Flag (Sigma), mouse anti-Flag M1 (Sigma), mouse anti-Flag M2 (Sigma), mouse anti-HA 16B12 (Biolegend), rat anti-HA (Roche), goat anti-AC9 (Santa Cruz Biotech), mouse anti-Golgin-97 (Thermo), rabbit anti-calnexin (Cell Signaling), mouse anti-Sodium/Potassium ATPase (Fisher).</p></sec><sec id="s4-3"><title>Fixed cell confocal imaging</title><p>Cells were transfected with the indicated construct(s) and then plated on glass coverslips coated with poly-L-lysine (0.0001%, Sigma) 24 hr later. For antibody feeding assays, cells were: (1) placed on ice and rinsed with ice-cold phosphate-buffered saline (PBS), (2) labeled by the addition of antibodies diluted 1:1000 in DMEM for 10 min, and (3) rinsed with room temperature PBS and allowed to traffic for 30 min by the addition of 37<bold>°</bold>C fresh media (DMEM + 10% fetal bovine serum) with or without a saturating concentration of β2AR agonist (10 μM isoproterenol, Sigma), V2R agonist (10 µM arginine-vasopressin, Sigma), MOR agonist (10 µM DAMGO, Sigma), or forskolin (10 µM, Sigma). For all assays, cells were rinsed with cold PBS and fixed by incubation in 3.7% formaldehyde (Fisher Scientific) diluted in modified BRB80 buffer (80 mM PIPES, 1 mM MgCl<sub>2</sub>, 1 mM CaCl<sub>2</sub>, pH 6.8) for 20 min at room temperature. Cells were then blocked in 2% Bovine Serum Albumin (Sigma) in PBS with permeabilization by 0.2% triton X-100 (Sigma). Primary antibody labeling was performed by the addition of antibodies diluted 1:1000 in blocking/permeabilization buffer for one hour at room temperature. Secondary labeling was performed by addition of the following antibodies diluted at 1:500 in blocking/permeabilization buffer for 20 min at room temperature: Alexa Fluor 555 or 488 donkey anti-mouse (Invitrogen), Alexa Fluor 555 or 488 donkey anti-rabbit (Invitrogen), Alexa Fluor 488 or 555 goat anti-rat (Invitrogen), or Alexa Fluor 488 donkey anti-sheep (Life Technologies). Specimens were mounted using ProLong Gold antifade reagent (Life Technologies).</p><p>Fixed cells were imaged by spinning disc confocal microscope (Nikon TE-2000 with Yokogawa confocal scanner unit CSU22) using a 100X NA 1.45 objective. A 488 nm argon laser and a 568 nm argon/krypton laser (Melles Griot) were used as light sources.</p></sec><sec id="s4-4"><title>Microscope image acquisition and image analysis</title><p>Spinning disc images were collected using an electron multiplying CCD camera (Andor iXon 897) operated in the linear range controlled by Micro-Manager software (<ext-link ext-link-type="uri" xlink:href="https://www.micro-manager.org">https://www.micro-manager.org</ext-link>). Images were processed at full bit depth for all analysis and rendered for display by converting to RGB format using ImageJ software (<ext-link ext-link-type="uri" xlink:href="http://imagej.nih.gov/ij">http://imagej.nih.gov/ij</ext-link>) and linear look up table. The number of endosomes was quantified by thresholding images and the ParticleTracker ImageJ plugin.</p></sec><sec id="s4-5"><title>Live-cell confocal imaging</title><p>Live cell imaging was carried out using Yokagawa CSU22 spinning disk confocal microscope with a × 100, 1.4 numerical aperture, oil objective and a CO2°C and 37°C temperature-controlled incubator. A 488 nm argon laser and a 568 nm argon/krypton laser (Melles Griot) were used as light sources for imaging EGFP and Flag signals, respectively. Cells expressing both Flag-tagged receptor and the indicated nanobody–EGFP were plated onto glass coverslips. Receptors were surface labelled by addition of M1 anti-Flag antibody (1:1000, Sigma) conjugated to Alexa 555 (A10470, Invitrogen) to the media for 30 min, as described previously. Indicated agonist (isoprenaline, Sigma) or antagonist (CGP-12177, Tocris) (alprenolol, Sigma) were added and cells were imaged every 3 s for 20 min in DMEM without phenol red supplemented with 30 mM HEPES, pH 7.4 (UCSF Cell Culture Facility). Time-lapse images were acquired with a Cascade II EM charge-coupled-device (CCD) camera (Photometrics) driven by Micro-Manager 1.4 (<ext-link ext-link-type="uri" xlink:href="http://www.micro-manager.org">http://www.micro-manager.org</ext-link>).</p></sec><sec id="s4-6"><title>Endosome immunoisolation</title><p>Cells were transfected with the indicated construct(s) 48 hr before lysis and plated onto 60 mm cell culture dishes 24 hr before lysis. Cells were allowed to traffic for 30 min by the addition of 37<bold>°</bold>C fresh media (DMEM + 10% fetal bovine serum) with or without a saturating concentration of the indicated agonist. Cells were then placed on ice, washed with ice-cold PBS, and scraped into an isotonic homogenization buffer (10 mM HEPES, 100 mM KCl, 25 mM sucrose, Complete protease inhibitor (Roche), pH 7.2) and passaged 20 times through a 22 G BD PrecisionGlide Needle. Whole cell lysates were then spun down at 1000 G for 10 min at 4°C and the pellets discarded. The supernatant was then bound to Early Endosome Antigen one mouse antibody (1:250, Fisher Scientific) and anti-mouse IgG magnetic microbeads (Miltenyi Biotech) overnight. Endosomes were then bound to magnetic columns which were blocked with 3% BSA and washed with PBS. Proteins in the isolated fraction were eluted with 0.1% Triton-X and characterized by western blot.</p></sec><sec id="s4-7"><title>Surface biotinylation</title><p>Cells were transfected with the indicated construct(s) 48 hr before lysis and plated onto 60 mm cell culture dishes coated with poly-L-lysine (0.0001%, Sigma) 24 hr before lysis. Cells were allowed to traffic for 30 min by the addition of 37<bold>°</bold>C fresh media (DMEM + 10% fetal bovine serum) with or without a saturating concentration of the indicated agonist. Cells were then placed on ice, washed with ice-cold PBS, and then surface labeled with EZ-link Sulfo-NHS-biotin (Pierce) for 30 min, rocking at 4°C. Reaction was then quenched with tris buffered saline (TBS) twice for 10 min. Cells were then placed on ice, washed with ice-cold PBS, and scraped into an isotonic homogenization buffer (10 mM HEPES, 100 mM KCl, 25 mM sucrose, Complete protease inhibitor (Roche), pH 7.2) and passaged 20 times through a 22 G BD PrecisionGlide Needle. Cell lysate was then bound to streptavidin agarose resin (Thermo) overnight. Resin was spun down and the supernatant discarded, resuspended and washed in ice-cold PBS, and characterized by western blot.</p></sec><sec id="s4-8"><title>Real-time cAMP assay in living cells</title><p>Real-time analysis of cAMP elevations were carried out in living HEK293 cells and in the absence of phosphodiesterase inhibitors using a were transfected with a plasmid encoding a cyclic-permuted luciferase reporter construct, based on a mutated RIIβB cAMP-binding domain from PKA (pGloSensor-20F, Promega), which produces rapid and reversible cAMP-dependent activation of luciferase activity in intact cells and is capable of detecting cAMP elevations in the absence of phosphodiesterase inhibitors. Cells were plated in 24-well dishes containing approximately 200,000 cells per well in 500 μl DMEM without phenol red and no serum and equilibrated to 37°C in a light-proof cabinet. An image of the plate was focused on a 512 × 512 pixel electron multiplying CCD sensor (Hamamatsu C9100-13), cells were equilibrated for 1 hr in the presence of 250 μg ml<sup>−1</sup> luciferin (Gold biosciences), and sequential luminescence images were collected every 10 s to obtain basal luminescence values. The camera shutter was closed, the cabinet opened and the indicated concentration of isoprenaline was bath applied, with gentle manual rocking before replacing in the dark cabinet and resuming luminescence image acquisition. In endocytic manipulation experiments, cells were pre-incubated with 30 μM Dyngo-4a (abcam Biochemicals) for 15 min. Every 10 s, sequential images were acquired using Micro-Manager (<ext-link ext-link-type="uri" xlink:href="http://www.micro-manager.org">http://www.micro-manager.org</ext-link>) and integrated luminescence intensity detected from each well was calculated after background subtraction and correction for vignetting using scripts written in MATLAB (MathWorks). In each multiwell plate, and for each experimental condition, a reference value of luminescence was measured in the presence of 5 μM forskolin, a manipulation that stimulates a moderate amount of receptor-independent activation of adenylyl cyclase. The average luminescence value—measured across duplicate wells—was normalized to the maximum luminescence value measured in the presence of 5 μM forskolin.</p></sec><sec id="s4-9"><title>Biochemical assay of cAMP accumulation</title><p>A biochemical assay of cAMP accumulation was used to determine the effects of AC mutation on catalytic activity, with high sensitivity and without dependence on subcellular location due to inhibition of cellular phosphodiesterases. Briefly, cells were pre-incubated in the presence of 1 mM IBMX (Sigma) for 30 min at 37°C in Dulbecco's modified Eagle's medium followed, and then incubated for an additional 10 min in absence or presence of isoproterenol (in the continued presence of IBMX), as indicated. Cells were quickly washed with ice-cold PBS and lysed by exposure to 0.1 M HCl for 10 min at room temperature. The cAMP concentration in lysates was determined using a commercial immunoassay (Direct cAMP ELISA kit, Enzo Life Sciences, Farmingdale, NY) according to the manufacturer’s instructions.</p></sec><sec id="s4-10"><title>Statistical analysis</title><p>Results are displayed as the mean of results from each experiment or data set, as indicated in figure legends. The statistical significance between conditions for experiments with two conditions was calculated using paired, two tailed t-tests. All statistical calculations were performed using Excel (Microsoft Office) or Prism (GraphPad). The threshold for significance was p&lt;0.05 and the coding for significance is reported as follows: (n.s.) p&gt;0.05, (*) p≤0.05, (**) p≤0.01.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank B Lobingier, G Peng, L Ripoll, M Stoeber and other current and past members of the von Zastrow laboratory for advice and critical discussions. We thank R D Mullins, R Sunahara and J Taunton for valuable discussion and suggestions. We thank M Soto-Velasquez and V Watts for valuable discussion and the generous gift of AC3/6 knockout cells. We thank the E Roth group for their generous support and lab equipment, and K Kurtz for assistance. This work was supported by grants from the US National Institutes of Health (DA010711 and DA012864 to MvZ; GM60419 to CWD; HL124049 to AAS; CA209891 to JSG). AL is an ARCS scholar.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Supervision, Validation, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con5"><p>Resources, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Resources, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Resources, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-58039-transrepform-v2.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided all main figures.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname> <given-names>JA</given-names></name><name><surname>Yu</surname> <given-names>JZ</given-names></name><name><surname>Donati</surname> <given-names>RJ</given-names></name><name><surname>Rasenick</surname> <given-names>MM</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Beta-adrenergic receptor stimulation promotes G alpha s internalization through lipid rafts: a study in living cells</article-title><source>Molecular Pharmacology</source><volume>67</volume><fpage>1493</fpage><lpage>1504</lpage><pub-id pub-id-type="doi">10.1124/mol.104.008342</pub-id><pub-id pub-id-type="pmid">15703379</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldwin</surname> <given-names>TA</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Brand</surname> <given-names>CS</given-names></name><name><surname>Watts</surname> <given-names>VJ</given-names></name><name><surname>Dessauer</surname> <given-names>CW</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Insights into the regulatory properties of human adenylyl cyclase type 9</article-title><source>Molecular Pharmacology</source><volume>95</volume><fpage>349</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1124/mol.118.114595</pub-id><pub-id pub-id-type="pmid">30696718</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Billington</surname> <given-names>CK</given-names></name><name><surname>Hall</surname> <given-names>IP</given-names></name><name><surname>Mundell</surname> <given-names>SJ</given-names></name><name><surname>Parent</surname> <given-names>JL</given-names></name><name><surname>Panettieri</surname> <given-names>RA</given-names></name><name><surname>Benovic</surname> <given-names>JL</given-names></name><name><surname>Penn</surname> <given-names>RB</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Inflammatory and contractile agents sensitize specific adenylyl cyclase isoforms in human airway smooth muscle</article-title><source>American Journal of Respiratory Cell and Molecular Biology</source><volume>21</volume><fpage>597</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1165/ajrcmb.21.5.3759</pub-id><pub-id pub-id-type="pmid">10536119</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birnbaumer</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Vasopressin receptors</article-title><source>Trends in Endocrinology &amp; Metabolism</source><volume>11</volume><fpage>406</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1016/S1043-2760(00)00304-0</pub-id><pub-id pub-id-type="pmid">11091117</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calebiro</surname> <given-names>D</given-names></name><name><surname>Nikolaev</surname> <given-names>VO</given-names></name><name><surname>Gagliani</surname> <given-names>MC</given-names></name><name><surname>de Filippis</surname> <given-names>T</given-names></name><name><surname>Dees</surname> <given-names>C</given-names></name><name><surname>Tacchetti</surname> <given-names>C</given-names></name><name><surname>Persani</surname> <given-names>L</given-names></name><name><surname>Lohse</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Persistent cAMP-signals triggered by internalized G-protein-coupled receptors</article-title><source>PLOS Biology</source><volume>7</volume><elocation-id>e1000172</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.1000172</pub-id><pub-id pub-id-type="pmid">19688034</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cancino</surname> <given-names>J</given-names></name><name><surname>Capalbo</surname> <given-names>A</given-names></name><name><surname>Di Campli</surname> <given-names>A</given-names></name><name><surname>Giannotta</surname> <given-names>M</given-names></name><name><surname>Rizzo</surname> <given-names>R</given-names></name><name><surname>Jung</surname> <given-names>JE</given-names></name><name><surname>Di Martino</surname> <given-names>R</given-names></name><name><surname>Persico</surname> <given-names>M</given-names></name><name><surname>Heinklein</surname> <given-names>P</given-names></name><name><surname>Sallese</surname> <given-names>M</given-names></name><name><surname>Luini</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Control systems of membrane transport at the interface between the endoplasmic reticulum and the golgi</article-title><source>Developmental Cell</source><volume>30</volume><fpage>280</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2014.06.018</pub-id><pub-id pub-id-type="pmid">25117681</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charest</surname> <given-names>PG</given-names></name><name><surname>Bouvier</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Palmitoylation of the V2 vasopressin receptor carboxyl tail enhances beta-arrestin recruitment leading to efficient receptor endocytosis and ERK1/2 activation</article-title><source>Journal of Biological Chemistry</source><volume>278</volume><fpage>41541</fpage><lpage>41551</lpage><pub-id pub-id-type="doi">10.1074/jbc.M306589200</pub-id><pub-id pub-id-type="pmid">12900404</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Harry</surname> <given-names>A</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Smit</surname> <given-names>MJ</given-names></name><name><surname>Bai</surname> <given-names>X</given-names></name><name><surname>Magnusson</surname> <given-names>R</given-names></name><name><surname>Pieroni</surname> <given-names>JP</given-names></name><name><surname>Weng</surname> <given-names>G</given-names></name><name><surname>Iyengar</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Adenylyl cyclase 6 is selectively regulated by protein kinase A phosphorylation in a region involved in galphas stimulation</article-title><source>PNAS</source><volume>94</volume><fpage>14100</fpage><lpage>14104</lpage><pub-id pub-id-type="doi">10.1073/pnas.94.25.14100</pub-id><pub-id pub-id-type="pmid">9391159</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname> <given-names>H</given-names></name><name><surname>Farquhar</surname> <given-names>MG</given-names></name></person-group><year iso-8601-date="1976">1976</year><article-title>Presence of adenylate cyclase activity in golgi and other fractions from rat liver. II. cytochemical localization within golgi and ER membranes</article-title><source>The Journal of Cell Biology</source><volume>70</volume><fpage>671</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1083/jcb.70.3.671</pub-id><pub-id pub-id-type="pmid">956270</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname> <given-names>RB</given-names></name><name><surname>Friedman</surname> <given-names>J</given-names></name><name><surname>Prashad</surname> <given-names>N</given-names></name><name><surname>Ruoho</surname> <given-names>AE</given-names></name></person-group><year iso-8601-date="1985">1985</year><article-title>Epinephrine-induced sequestration of the beta-adrenergic receptor in cultured S49 WT and cyc- lymphoma cells</article-title><source>Journal of Cyclic Nucleotide and Protein Phosphorylation Research</source><volume>10</volume><fpage>97</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">2984267</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cottrell</surname> <given-names>GS</given-names></name><name><surname>Padilla</surname> <given-names>BE</given-names></name><name><surname>Amadesi</surname> <given-names>S</given-names></name><name><surname>Poole</surname> <given-names>DP</given-names></name><name><surname>Murphy</surname> <given-names>JE</given-names></name><name><surname>Hardt</surname> <given-names>M</given-names></name><name><surname>Roosterman</surname> <given-names>D</given-names></name><name><surname>Steinhoff</surname> <given-names>M</given-names></name><name><surname>Bunnett</surname> <given-names>NW</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Endosomal endothelin-converting enzyme-1: a regulator of beta-arrestin-dependent ERK signaling</article-title><source>The Journal of Biological Chemistry</source><volume>284</volume><fpage>22411</fpage><lpage>22425</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.026674</pub-id><pub-id pub-id-type="pmid">19531493</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dessauer</surname> <given-names>CW</given-names></name><name><surname>Posner</surname> <given-names>BA</given-names></name><name><surname>Gilman</surname> <given-names>AG</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Visualizing signal transduction: receptors, G-proteins, and adenylate cyclases</article-title><source>Clinical Science</source><volume>91</volume><fpage>527</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1042/cs0910527</pub-id><pub-id pub-id-type="pmid">8942391</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Fiore</surname> <given-names>PP</given-names></name><name><surname>von Zastrow</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Endocytosis, signaling, and beyond</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>6</volume><elocation-id>a016865</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a016865</pub-id><pub-id pub-id-type="pmid">25085911</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feinstein</surname> <given-names>TN</given-names></name><name><surname>Yui</surname> <given-names>N</given-names></name><name><surname>Webber</surname> <given-names>MJ</given-names></name><name><surname>Wehbi</surname> <given-names>VL</given-names></name><name><surname>Stevenson</surname> <given-names>HP</given-names></name><name><surname>King</surname> <given-names>JD</given-names></name><name><surname>Hallows</surname> <given-names>KR</given-names></name><name><surname>Brown</surname> <given-names>D</given-names></name><name><surname>Bouley</surname> <given-names>R</given-names></name><name><surname>Vilardaga</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Noncanonical control of vasopressin receptor type 2 signaling by retromer and arrestin</article-title><source>Journal of Biological Chemistry</source><volume>288</volume><fpage>27849</fpage><lpage>27860</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.445098</pub-id><pub-id pub-id-type="pmid">23935101</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferguson</surname> <given-names>SS</given-names></name><name><surname>Downey</surname> <given-names>WE</given-names></name><name><surname>Colapietro</surname> <given-names>AM</given-names></name><name><surname>Barak</surname> <given-names>LS</given-names></name><name><surname>Ménard</surname> <given-names>L</given-names></name><name><surname>Caron</surname> <given-names>MG</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization</article-title><source>Science</source><volume>271</volume><fpage>363</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1126/science.271.5247.363</pub-id><pub-id pub-id-type="pmid">8553074</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrandon</surname> <given-names>S</given-names></name><name><surname>Feinstein</surname> <given-names>TN</given-names></name><name><surname>Castro</surname> <given-names>M</given-names></name><name><surname>Wang</surname> <given-names>B</given-names></name><name><surname>Bouley</surname> <given-names>R</given-names></name><name><surname>Potts</surname> <given-names>JT</given-names></name><name><surname>Gardella</surname> <given-names>TJ</given-names></name><name><surname>Vilardaga</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Sustained cyclic AMP production by parathyroid hormone receptor endocytosis</article-title><source>Nature Chemical Biology</source><volume>5</volume><fpage>734</fpage><lpage>742</lpage><pub-id pub-id-type="doi">10.1038/nchembio.206</pub-id><pub-id pub-id-type="pmid">19701185</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flesch</surname> <given-names>B</given-names></name><name><surname>Ntambi</surname> <given-names>E</given-names></name><name><surname>Neppert</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Biotinylation: a nonradioactive method for the identification of cell surface antigens in immunoprecipitates</article-title><source>Electrophoresis</source><volume>16</volume><fpage>757</fpage><lpage>762</lpage><pub-id pub-id-type="doi">10.1002/elps.11501601124</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname> <given-names>MH</given-names></name><name><surname>Tang</surname> <given-names>T</given-names></name><name><surname>Lai</surname> <given-names>NC</given-names></name><name><surname>Miyanohara</surname> <given-names>A</given-names></name><name><surname>Guo</surname> <given-names>T</given-names></name><name><surname>Tang</surname> <given-names>R</given-names></name><name><surname>Firth</surname> <given-names>AL</given-names></name><name><surname>Yuan</surname> <given-names>JX</given-names></name><name><surname>Hammond</surname> <given-names>HK</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Beneficial effects of adenylyl cyclase type 6 (AC6) expression persist using a catalytically inactive AC6 mutant</article-title><source>Molecular Pharmacology</source><volume>79</volume><fpage>381</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1124/mol.110.067298</pub-id><pub-id pub-id-type="pmid">21127130</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilman</surname> <given-names>AG</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>G proteins: transducers of Receptor-Generated signals</article-title><source>Annual Review of Biochemistry</source><volume>56</volume><fpage>615</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1146/annurev.bi.56.070187.003151</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilman</surname> <given-names>AG</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Transmembrane signaling, G proteins, and adenylyl cyclase</article-title><source>Harvey Lectures</source><volume>85</volume><fpage>153</fpage><lpage>172</lpage><pub-id pub-id-type="pmid">2519149</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodman</surname> <given-names>OB</given-names></name><name><surname>Krupnick</surname> <given-names>JG</given-names></name><name><surname>Santini</surname> <given-names>F</given-names></name><name><surname>Gurevich</surname> <given-names>VV</given-names></name><name><surname>Penn</surname> <given-names>RB</given-names></name><name><surname>Gagnon</surname> <given-names>AW</given-names></name><name><surname>Keen</surname> <given-names>JH</given-names></name><name><surname>Benovic</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor</article-title><source>Nature</source><volume>383</volume><fpage>447</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1038/383447a0</pub-id><pub-id pub-id-type="pmid">8837779</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hacker</surname> <given-names>BM</given-names></name><name><surname>Tomlinson</surname> <given-names>JE</given-names></name><name><surname>Wayman</surname> <given-names>GA</given-names></name><name><surname>Sultana</surname> <given-names>R</given-names></name><name><surname>Chan</surname> <given-names>G</given-names></name><name><surname>Villacres</surname> <given-names>E</given-names></name><name><surname>Disteche</surname> <given-names>C</given-names></name><name><surname>Storm</surname> <given-names>DR</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Cloning, chromosomal mapping, and regulatory properties of the human type 9 adenylyl cyclase (ADCY9)</article-title><source>Genomics</source><volume>50</volume><fpage>97</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1006/geno.1998.5293</pub-id><pub-id pub-id-type="pmid">9628827</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hammond</surname> <given-names>JC</given-names></name><name><surname>McCullumsmith</surname> <given-names>RE</given-names></name><name><surname>Funk</surname> <given-names>AJ</given-names></name><name><surname>Haroutunian</surname> <given-names>V</given-names></name><name><surname>Meador-Woodruff</surname> <given-names>JH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Evidence for abnormal forward trafficking of AMPA receptors in frontal cortex of elderly patients with schizophrenia</article-title><source>Neuropsychopharmacology</source><volume>35</volume><fpage>2110</fpage><lpage>2119</lpage><pub-id pub-id-type="doi">10.1038/npp.2010.87</pub-id><pub-id pub-id-type="pmid">20571483</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harden</surname> <given-names>TK</given-names></name><name><surname>Cotton</surname> <given-names>CU</given-names></name><name><surname>Waldo</surname> <given-names>GL</given-names></name><name><surname>Lutton</surname> <given-names>JK</given-names></name><name><surname>Perkins</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="1980">1980</year><article-title>Catecholamine-induced alteration in sedimentation behavior of membrane bound beta-adrenergic receptors</article-title><source>Science</source><volume>210</volume><fpage>441</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1126/science.6254143</pub-id><pub-id pub-id-type="pmid">6254143</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hilger</surname> <given-names>D</given-names></name><name><surname>Masureel</surname> <given-names>M</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structure and dynamics of GPCR signaling complexes</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>25</volume><fpage>4</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1038/s41594-017-0011-7</pub-id><pub-id pub-id-type="pmid">29323277</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hynes</surname> <given-names>TR</given-names></name><name><surname>Mervine</surname> <given-names>SM</given-names></name><name><surname>Yost</surname> <given-names>EA</given-names></name><name><surname>Sabo</surname> <given-names>JL</given-names></name><name><surname>Berlot</surname> <given-names>CH</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Live cell imaging of gs and the beta2-adrenergic receptor demonstrates that both alphas and beta1gamma7 internalize upon stimulation and exhibit similar trafficking patterns that differ from that of the beta2-adrenergic receptor</article-title><source>The Journal of Biological Chemistry</source><volume>279</volume><fpage>44101</fpage><lpage>44112</lpage><pub-id pub-id-type="doi">10.1074/jbc.M405151200</pub-id><pub-id pub-id-type="pmid">15297467</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inda</surname> <given-names>C</given-names></name><name><surname>dos Santos Claro</surname> <given-names>PA</given-names></name><name><surname>Bonfiglio</surname> <given-names>JJ</given-names></name><name><surname>Senin</surname> <given-names>SA</given-names></name><name><surname>Maccarrone</surname> <given-names>G</given-names></name><name><surname>Turck</surname> <given-names>CW</given-names></name><name><surname>Silberstein</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Different cAMP sources are critically involved in G protein–coupled receptor CRHR1 signaling</article-title><source>Journal of Cell Biology</source><volume>214</volume><fpage>181</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1083/jcb.201512075</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Innamorati</surname> <given-names>G</given-names></name><name><surname>Sadeghi</surname> <given-names>H</given-names></name><name><surname>Eberle</surname> <given-names>AN</given-names></name><name><surname>Birnbaumer</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Phosphorylation of the V2 vasopressin receptor</article-title><source>Journal of Biological Chemistry</source><volume>272</volume><fpage>2486</fpage><lpage>2492</lpage><pub-id pub-id-type="doi">10.1074/jbc.272.4.2486</pub-id><pub-id pub-id-type="pmid">8999963</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Innamorati</surname> <given-names>G</given-names></name><name><surname>Sadeghi</surname> <given-names>HM</given-names></name><name><surname>Tran</surname> <given-names>NT</given-names></name><name><surname>Birnbaumer</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>A serine cluster prevents recycling of the V2 vasopressin receptor</article-title><source>PNAS</source><volume>95</volume><fpage>2222</fpage><lpage>2226</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.5.2222</pub-id><pub-id pub-id-type="pmid">9482866</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irannejad</surname> <given-names>R</given-names></name><name><surname>Tomshine</surname> <given-names>JC</given-names></name><name><surname>Tomshine</surname> <given-names>JR</given-names></name><name><surname>Chevalier</surname> <given-names>M</given-names></name><name><surname>Mahoney</surname> <given-names>JP</given-names></name><name><surname>Steyaert</surname> <given-names>J</given-names></name><name><surname>Rasmussen</surname> <given-names>SG</given-names></name><name><surname>Sunahara</surname> <given-names>RK</given-names></name><name><surname>El-Samad</surname> <given-names>H</given-names></name><name><surname>Huang</surname> <given-names>B</given-names></name><name><surname>von Zastrow</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Conformational biosensors reveal GPCR signalling from endosomes</article-title><source>Nature</source><volume>495</volume><fpage>534</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1038/nature12000</pub-id><pub-id pub-id-type="pmid">23515162</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irannejad</surname> <given-names>R</given-names></name><name><surname>Tsvetanova</surname> <given-names>NG</given-names></name><name><surname>Lobingier</surname> <given-names>BT</given-names></name><name><surname>von Zastrow</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Effects of endocytosis on receptor-mediated signaling</article-title><source>Current Opinion in Cell Biology</source><volume>35</volume><fpage>137</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2015.05.005</pub-id><pub-id pub-id-type="pmid">26057614</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jong</surname> <given-names>YI</given-names></name><name><surname>Harmon</surname> <given-names>SK</given-names></name><name><surname>O'Malley</surname> <given-names>KL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>GPCR signalling from within the cell</article-title><source>British Journal of Pharmacology</source><volume>175</volume><fpage>4026</fpage><lpage>4035</lpage><pub-id pub-id-type="doi">10.1111/bph.14023</pub-id><pub-id pub-id-type="pmid">28872669</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keith</surname> <given-names>DE</given-names></name><name><surname>Anton</surname> <given-names>B</given-names></name><name><surname>Murray</surname> <given-names>SR</given-names></name><name><surname>Zaki</surname> <given-names>PA</given-names></name><name><surname>Chu</surname> <given-names>PC</given-names></name><name><surname>Lissin</surname> <given-names>DV</given-names></name><name><surname>Monteillet-Agius</surname> <given-names>G</given-names></name><name><surname>Stewart</surname> <given-names>PL</given-names></name><name><surname>Evans</surname> <given-names>CJ</given-names></name><name><surname>von Zastrow</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>mu-Opioid receptor internalization: opiate drugs have differential effects on a conserved endocytic mechanism <italic>in</italic> vitro and in the mammalian brain</article-title><source>Molecular Pharmacology</source><volume>53</volume><fpage>377</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1124/mol.53.3.377</pub-id><pub-id pub-id-type="pmid">9495801</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kieffer</surname> <given-names>BL</given-names></name><name><surname>Evans</surname> <given-names>CJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Opioid receptors: from binding sites to visible molecules in vivo</article-title><source>Neuropharmacology</source><volume>56</volume><fpage>205</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2008.07.033</pub-id><pub-id pub-id-type="pmid">18718480</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname> <given-names>U</given-names></name><name><surname>Müller</surname> <given-names>C</given-names></name><name><surname>Chu</surname> <given-names>P</given-names></name><name><surname>Birnbaumer</surname> <given-names>M</given-names></name><name><surname>von Zastrow</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Heterologous inhibition of G protein-coupled receptor endocytosis mediated by receptor-specific trafficking of beta-arrestins</article-title><source>Journal of Biological Chemistry</source><volume>276</volume><fpage>17442</fpage><lpage>17447</lpage><pub-id pub-id-type="doi">10.1074/jbc.M009214200</pub-id><pub-id pub-id-type="pmid">11278476</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotowski</surname> <given-names>SJ</given-names></name><name><surname>Hopf</surname> <given-names>FW</given-names></name><name><surname>Seif</surname> <given-names>T</given-names></name><name><surname>Bonci</surname> <given-names>A</given-names></name><name><surname>von Zastrow</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Endocytosis promotes rapid dopaminergic signaling</article-title><source>Neuron</source><volume>71</volume><fpage>278</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2011.05.036</pub-id><pub-id pub-id-type="pmid">21791287</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kriebel</surname> <given-names>PW</given-names></name><name><surname>Barr</surname> <given-names>VA</given-names></name><name><surname>Rericha</surname> <given-names>EC</given-names></name><name><surname>Zhang</surname> <given-names>G</given-names></name><name><surname>Parent</surname> <given-names>CA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Collective cell migration requires vesicular trafficking for chemoattractant delivery at the trailing edge</article-title><source>Journal of Cell Biology</source><volume>183</volume><fpage>949</fpage><lpage>961</lpage><pub-id pub-id-type="doi">10.1083/jcb.200808105</pub-id><pub-id pub-id-type="pmid">19047467</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krupinski</surname> <given-names>J</given-names></name><name><surname>Coussen</surname> <given-names>F</given-names></name><name><surname>Bakalyar</surname> <given-names>HA</given-names></name><name><surname>Tang</surname> <given-names>WJ</given-names></name><name><surname>Feinstein</surname> <given-names>PG</given-names></name><name><surname>Orth</surname> <given-names>K</given-names></name><name><surname>Slaughter</surname> <given-names>C</given-names></name><name><surname>Reed</surname> <given-names>RR</given-names></name><name><surname>Gilman</surname> <given-names>AG</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Adenylyl cyclase amino acid sequence: possible channel- or transporter-like structure</article-title><source>Science</source><volume>244</volume><fpage>1558</fpage><lpage>1564</lpage><pub-id pub-id-type="doi">10.1126/science.2472670</pub-id><pub-id pub-id-type="pmid">2472670</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lefkowitz</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Seven transmembrane receptors: something old, something new</article-title><source>Acta Physiologica</source><volume>190</volume><fpage>9</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1111/j.1365-201X.2007.01693.x</pub-id><pub-id pub-id-type="pmid">17428228</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lobingier</surname> <given-names>BT</given-names></name><name><surname>von Zastrow</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>When trafficking and signaling mix: how subcellular location shapes G protein-coupled receptor activation of heterotrimeric G proteins</article-title><source>Traffic</source><volume>20</volume><fpage>130</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1111/tra.12634</pub-id><pub-id pub-id-type="pmid">30578610</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lohse</surname> <given-names>MJ</given-names></name><name><surname>Benovic</surname> <given-names>JL</given-names></name><name><surname>Codina</surname> <given-names>J</given-names></name><name><surname>Caron</surname> <given-names>MG</given-names></name><name><surname>Lefkowitz</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>beta-Arrestin: a protein that regulates beta-adrenergic receptor function</article-title><source>Science</source><volume>248</volume><fpage>1547</fpage><lpage>1550</lpage><pub-id pub-id-type="doi">10.1126/science.2163110</pub-id><pub-id pub-id-type="pmid">2163110</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lohse</surname> <given-names>MJ</given-names></name><name><surname>Calebiro</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Cell biology: receptor signals come in waves</article-title><source>Nature</source><volume>495</volume><fpage>457</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1038/nature12086</pub-id><pub-id pub-id-type="pmid">23515157</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lohse</surname> <given-names>MJ</given-names></name><name><surname>Hofmann</surname> <given-names>KP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Spatial and temporal aspects of signaling by G-Protein-Coupled receptors</article-title><source>Molecular Pharmacology</source><volume>88</volume><fpage>572</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1124/mol.115.100248</pub-id><pub-id pub-id-type="pmid">26184590</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macia</surname> <given-names>E</given-names></name><name><surname>Ehrlich</surname> <given-names>M</given-names></name><name><surname>Massol</surname> <given-names>R</given-names></name><name><surname>Boucrot</surname> <given-names>E</given-names></name><name><surname>Brunner</surname> <given-names>C</given-names></name><name><surname>Kirchhausen</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Dynasore, a cell-permeable inhibitor of dynamin</article-title><source>Developmental Cell</source><volume>10</volume><fpage>839</fpage><lpage>850</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2006.04.002</pub-id><pub-id pub-id-type="pmid">16740485</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marrari</surname> <given-names>Y</given-names></name><name><surname>Crouthamel</surname> <given-names>M</given-names></name><name><surname>Irannejad</surname> <given-names>R</given-names></name><name><surname>Wedegaertner</surname> <given-names>PB</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Assembly and trafficking of heterotrimeric G proteins</article-title><source>Biochemistry</source><volume>46</volume><fpage>7665</fpage><lpage>7677</lpage><pub-id pub-id-type="doi">10.1021/bi700338m</pub-id><pub-id pub-id-type="pmid">17559193</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masters</surname> <given-names>SB</given-names></name><name><surname>Miller</surname> <given-names>RT</given-names></name><name><surname>Chi</surname> <given-names>MH</given-names></name><name><surname>Chang</surname> <given-names>FH</given-names></name><name><surname>Beiderman</surname> <given-names>B</given-names></name><name><surname>Lopez</surname> <given-names>NG</given-names></name><name><surname>Bourne</surname> <given-names>HR</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Mutations in the GTP-binding site of GS alpha alter stimulation of adenylyl cyclase</article-title><source>The Journal of Biological Chemistry</source><volume>264</volume><fpage>15467</fpage><lpage>15474</lpage><pub-id pub-id-type="pmid">2549064</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCluskey</surname> <given-names>A</given-names></name><name><surname>Daniel</surname> <given-names>JA</given-names></name><name><surname>Hadzic</surname> <given-names>G</given-names></name><name><surname>Chau</surname> <given-names>N</given-names></name><name><surname>Clayton</surname> <given-names>EL</given-names></name><name><surname>Mariana</surname> <given-names>A</given-names></name><name><surname>Whiting</surname> <given-names>A</given-names></name><name><surname>Gorgani</surname> <given-names>NN</given-names></name><name><surname>Lloyd</surname> <given-names>J</given-names></name><name><surname>Quan</surname> <given-names>A</given-names></name><name><surname>Moshkanbaryans</surname> <given-names>L</given-names></name><name><surname>Krishnan</surname> <given-names>S</given-names></name><name><surname>Perera</surname> <given-names>S</given-names></name><name><surname>Chircop</surname> <given-names>M</given-names></name><name><surname>von Kleist</surname> <given-names>L</given-names></name><name><surname>McGeachie</surname> <given-names>AB</given-names></name><name><surname>Howes</surname> <given-names>MT</given-names></name><name><surname>Parton</surname> <given-names>RG</given-names></name><name><surname>Campbell</surname> <given-names>M</given-names></name><name><surname>Sakoff</surname> <given-names>JA</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Sun</surname> <given-names>JY</given-names></name><name><surname>Robertson</surname> <given-names>MJ</given-names></name><name><surname>Deane</surname> <given-names>FM</given-names></name><name><surname>Nguyen</surname> <given-names>TH</given-names></name><name><surname>Meunier</surname> <given-names>FA</given-names></name><name><surname>Cousin</surname> <given-names>MA</given-names></name><name><surname>Robinson</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Building a better dynasore: the dyngo compounds potently inhibit dynamin and endocytosis</article-title><source>Traffic</source><volume>14</volume><fpage>1272</fpage><lpage>1289</lpage><pub-id pub-id-type="doi">10.1111/tra.12119</pub-id><pub-id pub-id-type="pmid">24025110</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mullershausen</surname> <given-names>F</given-names></name><name><surname>Zecri</surname> <given-names>F</given-names></name><name><surname>Cetin</surname> <given-names>C</given-names></name><name><surname>Billich</surname> <given-names>A</given-names></name><name><surname>Guerini</surname> <given-names>D</given-names></name><name><surname>Seuwen</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors</article-title><source>Nature Chemical Biology</source><volume>5</volume><fpage>428</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1038/nchembio.173</pub-id><pub-id pub-id-type="pmid">19430484</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navarro</surname> <given-names>G</given-names></name><name><surname>Cordomí</surname> <given-names>A</given-names></name><name><surname>Casadó-Anguera</surname> <given-names>V</given-names></name><name><surname>Moreno</surname> <given-names>E</given-names></name><name><surname>Cai</surname> <given-names>NS</given-names></name><name><surname>Cortés</surname> <given-names>A</given-names></name><name><surname>Canela</surname> <given-names>EI</given-names></name><name><surname>Dessauer</surname> <given-names>CW</given-names></name><name><surname>Casadó</surname> <given-names>V</given-names></name><name><surname>Pardo</surname> <given-names>L</given-names></name><name><surname>Lluís</surname> <given-names>C</given-names></name><name><surname>Ferré</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Evidence for functional pre-coupled complexes of receptor heteromers and adenylyl cyclase</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>1242</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-03522-3</pub-id><pub-id pub-id-type="pmid">29593213</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Banion</surname> <given-names>CP</given-names></name><name><surname>Vickerman</surname> <given-names>BM</given-names></name><name><surname>Haar</surname> <given-names>L</given-names></name><name><surname>Lawrence</surname> <given-names>DS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Compartmentalized cAMP generation by engineered photoactivated adenylyl cyclases</article-title><source>Cell Chemical Biology</source><volume>26</volume><fpage>1393</fpage><lpage>1406</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2019.07.004</pub-id><pub-id pub-id-type="pmid">31353320</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Hayre</surname> <given-names>M</given-names></name><name><surname>Eichel</surname> <given-names>K</given-names></name><name><surname>Avino</surname> <given-names>S</given-names></name><name><surname>Zhao</surname> <given-names>X</given-names></name><name><surname>Steffen</surname> <given-names>DJ</given-names></name><name><surname>Feng</surname> <given-names>X</given-names></name><name><surname>Kawakami</surname> <given-names>K</given-names></name><name><surname>Aoki</surname> <given-names>J</given-names></name><name><surname>Messer</surname> <given-names>K</given-names></name><name><surname>Sunahara</surname> <given-names>R</given-names></name><name><surname>Inoue</surname> <given-names>A</given-names></name><name><surname>von Zastrow</surname> <given-names>M</given-names></name><name><surname>Gutkind</surname> <given-names>JS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genetic evidence that β-arrestins are dispensable for the initiation of β<sub>2</sub>-adrenergic receptor signaling to ERK</article-title><source>Science Signaling</source><volume>10</volume><elocation-id>eaal3395</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aal3395</pub-id><pub-id pub-id-type="pmid">28634209</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oakley</surname> <given-names>RH</given-names></name><name><surname>Laporte</surname> <given-names>SA</given-names></name><name><surname>Holt</surname> <given-names>JA</given-names></name><name><surname>Barak</surname> <given-names>LS</given-names></name><name><surname>Caron</surname> <given-names>MG</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Association of beta-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization</article-title><source>Journal of Biological Chemistry</source><volume>274</volume><fpage>32248</fpage><lpage>32257</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.45.32248</pub-id><pub-id pub-id-type="pmid">10542263</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paterson</surname> <given-names>JM</given-names></name><name><surname>Smith</surname> <given-names>SM</given-names></name><name><surname>Simpson</surname> <given-names>J</given-names></name><name><surname>Grace</surname> <given-names>OC</given-names></name><name><surname>Sosunov</surname> <given-names>AA</given-names></name><name><surname>Bell</surname> <given-names>JE</given-names></name><name><surname>Antoni</surname> <given-names>FA</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Characterisation of human adenylyl cyclase IX reveals inhibition by Ca(2+)/Calcineurin and differential mRNA plyadenylation</article-title><source>Journal of Neurochemistry</source><volume>75</volume><fpage>1358</fpage><lpage>1367</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.2000.0751358.x</pub-id><pub-id pub-id-type="pmid">10987815</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Premont</surname> <given-names>RT</given-names></name><name><surname>Matsuoka</surname> <given-names>I</given-names></name><name><surname>Mattei</surname> <given-names>MG</given-names></name><name><surname>Pouille</surname> <given-names>Y</given-names></name><name><surname>Defer</surname> <given-names>N</given-names></name><name><surname>Hanoune</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Identification and characterization of a widely expressed form of adenylyl cyclase</article-title><source>Journal of Biological Chemistry</source><volume>271</volume><fpage>13900</fpage><lpage>13907</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.23.13900</pub-id><pub-id pub-id-type="pmid">8662814</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rochdi</surname> <given-names>MD</given-names></name><name><surname>Vargas</surname> <given-names>GA</given-names></name><name><surname>Carpentier</surname> <given-names>E</given-names></name><name><surname>Oligny-Longpré</surname> <given-names>G</given-names></name><name><surname>Chen</surname> <given-names>S</given-names></name><name><surname>Kovoor</surname> <given-names>A</given-names></name><name><surname>Gitelman</surname> <given-names>SE</given-names></name><name><surname>Rosenthal</surname> <given-names>SM</given-names></name><name><surname>von Zastrow</surname> <given-names>M</given-names></name><name><surname>Bouvier</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Functional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments</article-title><source>Molecular Pharmacology</source><volume>77</volume><fpage>836</fpage><lpage>845</lpage><pub-id pub-id-type="doi">10.1124/mol.109.061804</pub-id><pub-id pub-id-type="pmid">20159941</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenbaum</surname> <given-names>DM</given-names></name><name><surname>Rasmussen</surname> <given-names>SG</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The structure and function of G-protein-coupled receptors</article-title><source>Nature</source><volume>459</volume><fpage>356</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1038/nature08144</pub-id><pub-id pub-id-type="pmid">19458711</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadana</surname> <given-names>R</given-names></name><name><surname>Dessauer</surname> <given-names>CW</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Physiological roles for G protein-regulated adenylyl cyclase isoforms: insights from knockout and overexpression studies</article-title><source>Neurosignals</source><volume>17</volume><fpage>5</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1159/000166277</pub-id><pub-id pub-id-type="pmid">18948702</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slessareva</surname> <given-names>JE</given-names></name><name><surname>Routt</surname> <given-names>SM</given-names></name><name><surname>Temple</surname> <given-names>B</given-names></name><name><surname>Bankaitis</surname> <given-names>VA</given-names></name><name><surname>Dohlman</surname> <given-names>HG</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Activation of the phosphatidylinositol 3-kinase Vps34 by a G protein alpha subunit at the endosome</article-title><source>Cell</source><volume>126</volume><fpage>191</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.04.045</pub-id><pub-id pub-id-type="pmid">16839886</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Small</surname> <given-names>KM</given-names></name><name><surname>Brown</surname> <given-names>KM</given-names></name><name><surname>Theiss</surname> <given-names>CT</given-names></name><name><surname>Seman</surname> <given-names>CA</given-names></name><name><surname>Weiss</surname> <given-names>ST</given-names></name><name><surname>Liggett</surname> <given-names>SB</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>An ile to met polymorphism in the catalytic domain of adenylyl cyclase type 9 confers reduced ??2-adrenergic receptor stimulation</article-title><source>Pharmacogenetics</source><volume>13</volume><fpage>535</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1097/00008571-200309000-00002</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soto-Velasquez</surname> <given-names>M</given-names></name><name><surname>Hayes</surname> <given-names>MP</given-names></name><name><surname>Alpsoy</surname> <given-names>A</given-names></name><name><surname>Dykhuizen</surname> <given-names>EC</given-names></name><name><surname>Watts</surname> <given-names>VJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A novel CRISPR/Cas9-Based cellular model to explore adenylyl cyclase and cAMP signaling</article-title><source>Molecular Pharmacology</source><volume>94</volume><fpage>963</fpage><lpage>972</lpage><pub-id pub-id-type="doi">10.1124/mol.118.111849</pub-id><pub-id pub-id-type="pmid">29950405</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiegel</surname> <given-names>AM</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Signal transduction by guanine nucleotide binding proteins</article-title><source>Molecular and Cellular Endocrinology</source><volume>49</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/0303-7207(87)90058-X</pub-id><pub-id pub-id-type="pmid">2435586</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staehelin</surname> <given-names>M</given-names></name><name><surname>Simons</surname> <given-names>P</given-names></name><name><surname>Jaeggi</surname> <given-names>K</given-names></name><name><surname>Wigger</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="1983">1983</year><article-title>CGP-12177. A hydrophilic beta-adrenergic receptor radioligand reveals high affinity binding of agonists to intact cells</article-title><source>The Journal of Biological Chemistry</source><volume>258</volume><fpage>3496</fpage><lpage>3502</lpage><pub-id pub-id-type="pmid">6131886</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stallaert</surname> <given-names>W</given-names></name><name><surname>van der Westhuizen</surname> <given-names>ET</given-names></name><name><surname>Schönegge</surname> <given-names>AM</given-names></name><name><surname>Plouffe</surname> <given-names>B</given-names></name><name><surname>Hogue</surname> <given-names>M</given-names></name><name><surname>Lukashova</surname> <given-names>V</given-names></name><name><surname>Inoue</surname> <given-names>A</given-names></name><name><surname>Ishida</surname> <given-names>S</given-names></name><name><surname>Aoki</surname> <given-names>J</given-names></name><name><surname>Le Gouill</surname> <given-names>C</given-names></name><name><surname>Bouvier</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Purinergic receptor transactivation by the <italic>β</italic><sub>2</sub>-Adrenergic Receptor Increases Intracellular Ca<sup><sub>2</sub>+</sup> in nonexcitable cells</article-title><source>Molecular Pharmacology</source><volume>91</volume><fpage>533</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1124/mol.116.106419</pub-id><pub-id pub-id-type="pmid">28280061</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoeber</surname> <given-names>M</given-names></name><name><surname>Jullié</surname> <given-names>D</given-names></name><name><surname>Lobingier</surname> <given-names>BT</given-names></name><name><surname>Laeremans</surname> <given-names>T</given-names></name><name><surname>Steyaert</surname> <given-names>J</given-names></name><name><surname>Schiller</surname> <given-names>PW</given-names></name><name><surname>Manglik</surname> <given-names>A</given-names></name><name><surname>von Zastrow</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A genetically encoded biosensor reveals location Bias of opioid drug action</article-title><source>Neuron</source><volume>98</volume><fpage>963</fpage><lpage>976</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2018.04.021</pub-id><pub-id pub-id-type="pmid">29754753</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stryer</surname> <given-names>L</given-names></name><name><surname>Bourne</surname> <given-names>HR</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>G proteins: a family of signal transducers</article-title><source>Annual Review of Cell Biology</source><volume>2</volume><fpage>391</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1146/annurev.cb.02.110186.002135</pub-id><pub-id pub-id-type="pmid">3103658</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sunahara</surname> <given-names>RK</given-names></name><name><surname>Dessauer</surname> <given-names>CW</given-names></name><name><surname>Gilman</surname> <given-names>AG</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Complexity and diversity of mammalian adenylyl cyclases</article-title><source>Annual Review of Pharmacology and Toxicology</source><volume>36</volume><fpage>461</fpage><lpage>480</lpage><pub-id pub-id-type="doi">10.1146/annurev.pa.36.040196.002333</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sutherland</surname> <given-names>EW</given-names></name></person-group><year iso-8601-date="1971">1971</year><chapter-title>Nobel Lectures in Physiology or Medicine</chapter-title><person-group person-group-type="editor"><name><surname>Lindsten</surname> <given-names>J</given-names></name></person-group><source>Studies on the Mechanism of Hormone Action</source><publisher-name>World Scientific Publishing Co</publisher-name><fpage>5</fpage><lpage>22</lpage></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname> <given-names>Y</given-names></name><name><surname>Hu</surname> <given-names>LA</given-names></name><name><surname>Miller</surname> <given-names>WE</given-names></name><name><surname>Ringstad</surname> <given-names>N</given-names></name><name><surname>Hall</surname> <given-names>RA</given-names></name><name><surname>Pitcher</surname> <given-names>JA</given-names></name><name><surname>DeCamilli</surname> <given-names>P</given-names></name><name><surname>Lefkowitz</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Identification of the endophilins (SH3p4/p8/p13) as novel binding partners for the beta1-adrenergic receptor</article-title><source>PNAS</source><volume>96</volume><fpage>12559</fpage><lpage>12564</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.22.12559</pub-id><pub-id pub-id-type="pmid">10535961</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tantisira</surname> <given-names>KG</given-names></name><name><surname>Small</surname> <given-names>KM</given-names></name><name><surname>Litonjua</surname> <given-names>AA</given-names></name><name><surname>Weiss</surname> <given-names>ST</given-names></name><name><surname>Liggett</surname> <given-names>SB</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Molecular properties and pharmacogenetics of a polymorphism of adenylyl cyclase type 9 in asthma: interaction between beta-agonist and corticosteroid pathways</article-title><source>Human Molecular Genetics</source><volume>14</volume><fpage>1671</fpage><lpage>1677</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddi175</pub-id><pub-id pub-id-type="pmid">15879435</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname> <given-names>SS</given-names></name><name><surname>Zhang</surname> <given-names>P</given-names></name><name><surname>Steichen</surname> <given-names>JM</given-names></name><name><surname>Keshwani</surname> <given-names>MM</given-names></name><name><surname>Kornev</surname> <given-names>AP</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>PKA: lessons learned after twenty years</article-title><source>Biochimica Et Biophysica Acta (BBA) - Proteins and Proteomics</source><volume>1834</volume><fpage>1271</fpage><lpage>1278</lpage><pub-id pub-id-type="doi">10.1016/j.bbapap.2013.03.007</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Temkin</surname> <given-names>P</given-names></name><name><surname>Lauffer</surname> <given-names>B</given-names></name><name><surname>Jäger</surname> <given-names>S</given-names></name><name><surname>Cimermancic</surname> <given-names>P</given-names></name><name><surname>Krogan</surname> <given-names>NJ</given-names></name><name><surname>von Zastrow</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>SNX27 mediates retromer tubule entry and endosome-to-plasma membrane trafficking of signalling receptors</article-title><source>Nature Cell Biology</source><volume>13</volume><fpage>715</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1038/ncb2252</pub-id><pub-id pub-id-type="pmid">21602791</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tesmer</surname> <given-names>JJ</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Crystal structure of the catalytic domains of adenylyl cyclase in a complex with gs·GTPS</article-title><source>Science</source><volume>278</volume><fpage>1907</fpage><lpage>1916</lpage><pub-id pub-id-type="doi">10.1126/science.278.5345.1907</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomsen</surname> <given-names>ARB</given-names></name><name><surname>Plouffe</surname> <given-names>B</given-names></name><name><surname>Cahill</surname> <given-names>TJ</given-names></name><name><surname>Shukla</surname> <given-names>AK</given-names></name><name><surname>Tarrasch</surname> <given-names>JT</given-names></name><name><surname>Dosey</surname> <given-names>AM</given-names></name><name><surname>Kahsai</surname> <given-names>AW</given-names></name><name><surname>Strachan</surname> <given-names>RT</given-names></name><name><surname>Pani</surname> <given-names>B</given-names></name><name><surname>Mahoney</surname> <given-names>JP</given-names></name><name><surname>Huang</surname> <given-names>L</given-names></name><name><surname>Breton</surname> <given-names>B</given-names></name><name><surname>Heydenreich</surname> <given-names>FM</given-names></name><name><surname>Sunahara</surname> <given-names>RK</given-names></name><name><surname>Skiniotis</surname> <given-names>G</given-names></name><name><surname>Bouvier</surname> <given-names>M</given-names></name><name><surname>Lefkowitz</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>GPCR-G Protein-β-Arrestin Super-Complex mediates sustained G protein signaling</article-title><source>Cell</source><volume>166</volume><fpage>907</fpage><lpage>919</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.07.004</pub-id><pub-id pub-id-type="pmid">27499021</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname> <given-names>X</given-names></name><name><surname>Irannejad</surname> <given-names>R</given-names></name><name><surname>Bowman</surname> <given-names>SL</given-names></name><name><surname>Du</surname> <given-names>Y</given-names></name><name><surname>Puthenveedu</surname> <given-names>MA</given-names></name><name><surname>von Zastrow</surname> <given-names>M</given-names></name><name><surname>Benovic</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The α-Arrestin ARRDC3 regulates the endosomal residence time and intracellular signaling of the β2-Adrenergic receptor</article-title><source>Journal of Biological Chemistry</source><volume>291</volume><fpage>14510</fpage><lpage>14525</lpage><pub-id pub-id-type="doi">10.1074/jbc.M116.716589</pub-id><pub-id pub-id-type="pmid">27226565</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsvetanova</surname> <given-names>NG</given-names></name><name><surname>Trester-Zedlitz</surname> <given-names>M</given-names></name><name><surname>Newton</surname> <given-names>BW</given-names></name><name><surname>Riordan</surname> <given-names>DP</given-names></name><name><surname>Sundaram</surname> <given-names>AB</given-names></name><name><surname>Johnson</surname> <given-names>JR</given-names></name><name><surname>Krogan</surname> <given-names>NJ</given-names></name><name><surname>von Zastrow</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>G Protein-Coupled receptor endocytosis confers uniformity in responses to chemically distinct ligands</article-title><source>Molecular Pharmacology</source><volume>91</volume><fpage>145</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1124/mol.116.106369</pub-id><pub-id pub-id-type="pmid">27879340</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsvetanova</surname> <given-names>NG</given-names></name><name><surname>von Zastrow</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Spatial encoding of cyclic AMP signaling specificity by GPCR endocytosis</article-title><source>Nature Chemical Biology</source><volume>10</volume><fpage>1061</fpage><lpage>1065</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1665</pub-id><pub-id pub-id-type="pmid">25362359</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varandas</surname> <given-names>KC</given-names></name><name><surname>Irannejad</surname> <given-names>R</given-names></name><name><surname>von Zastrow</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Retromer endosome exit domains serve multiple trafficking destinations and regulate local G protein activation by GPCRs</article-title><source>Current Biology</source><volume>26</volume><fpage>3129</fpage><lpage>3142</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2016.09.052</pub-id><pub-id pub-id-type="pmid">27839977</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vilardaga</surname> <given-names>JP</given-names></name><name><surname>Jean-Alphonse</surname> <given-names>FG</given-names></name><name><surname>Gardella</surname> <given-names>TJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Endosomal generation of cAMP in GPCR signaling</article-title><source>Nature Chemical Biology</source><volume>10</volume><fpage>700</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1611</pub-id><pub-id pub-id-type="pmid">25271346</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Violin</surname> <given-names>JD</given-names></name><name><surname>DiPilato</surname> <given-names>LM</given-names></name><name><surname>Yildirim</surname> <given-names>N</given-names></name><name><surname>Elston</surname> <given-names>TC</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Lefkowitz</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>beta2-adrenergic receptor signaling and desensitization elucidated by quantitative modeling of real time cAMP dynamics</article-title><source>Journal of Biological Chemistry</source><volume>283</volume><fpage>2949</fpage><lpage>2961</lpage><pub-id pub-id-type="doi">10.1074/jbc.M707009200</pub-id><pub-id pub-id-type="pmid">18045878</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Zastrow</surname> <given-names>M</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Ligand-regulated internalization and recycling of human beta 2-adrenergic receptors between the plasma membrane and endosomes containing transferrin receptors</article-title><source>The Journal of Biological Chemistry</source><volume>267</volume><fpage>3530</fpage><lpage>3538</lpage><pub-id pub-id-type="pmid">1371121</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Zastrow</surname> <given-names>M</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Antagonist-dependent and -independent steps in the mechanism of adrenergic receptor internalization</article-title><source>The Journal of Biological Chemistry</source><volume>269</volume><fpage>18448</fpage><lpage>18452</lpage><pub-id pub-id-type="pmid">7518433</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>D</given-names></name><name><surname>Eraslan</surname> <given-names>B</given-names></name><name><surname>Wieland</surname> <given-names>T</given-names></name><name><surname>Hallström</surname> <given-names>B</given-names></name><name><surname>Hopf</surname> <given-names>T</given-names></name><name><surname>Zolg</surname> <given-names>DP</given-names></name><name><surname>Zecha</surname> <given-names>J</given-names></name><name><surname>Asplund</surname> <given-names>A</given-names></name><name><surname>Li</surname> <given-names>LH</given-names></name><name><surname>Meng</surname> <given-names>C</given-names></name><name><surname>Frejno</surname> <given-names>M</given-names></name><name><surname>Schmidt</surname> <given-names>T</given-names></name><name><surname>Schnatbaum</surname> <given-names>K</given-names></name><name><surname>Wilhelm</surname> <given-names>M</given-names></name><name><surname>Ponten</surname> <given-names>F</given-names></name><name><surname>Uhlen</surname> <given-names>M</given-names></name><name><surname>Gagneur</surname> <given-names>J</given-names></name><name><surname>Hahne</surname> <given-names>H</given-names></name><name><surname>Kuster</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A deep proteome and transcriptome abundance atlas of 29 healthy human tissues</article-title><source>Molecular Systems Biology</source><volume>15</volume><elocation-id>e8503</elocation-id><pub-id pub-id-type="doi">10.15252/msb.20188503</pub-id><pub-id pub-id-type="pmid">30777892</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wedegaertner</surname> <given-names>PB</given-names></name><name><surname>Bourne</surname> <given-names>HR</given-names></name><name><surname>von Zastrow</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Activation-induced subcellular redistribution of gs alpha</article-title><source>Molecular Biology of the Cell</source><volume>7</volume><fpage>1225</fpage><lpage>1233</lpage><pub-id pub-id-type="doi">10.1091/mbc.7.8.1225</pub-id><pub-id pub-id-type="pmid">8856666</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whistler</surname> <given-names>JL</given-names></name><name><surname>von Zastrow</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Morphine-activated opioid receptors elude desensitization by beta-arrestin</article-title><source>PNAS</source><volume>95</volume><fpage>9914</fpage><lpage>9919</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.17.9914</pub-id><pub-id pub-id-type="pmid">9707575</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.58039.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Linstedt</surname><given-names>Adam</given-names></name><role>Reviewing Editor</role><aff><institution>Carnegie Mellon University</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This work carefully and convincingly demonstrates that Gs activation during β-adrenergic receptor signaling drives endocytosis of a specific isoform of a downstream effector, adenyl cyclase 9, which contributes to cAMP production.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;G protein-regulated endocytic trafficking of adenylyl cyclase type 9&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Suzanne Pfeffer as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as <italic>eLife</italic> papers without additional data, even if they feel that they would make the manuscript stronger. Thus the revisions requested below only address clarity and presentation.</p><p>Summary:</p><p>This study addresses the question of adenyl cyclase (AC) endocytosis during GPCR signaling. Morphological and biochemical experiments primarily in transfected HEK293 cells show that two Gs-coupled GPCRs drive isoform specific endocytosis of AC9 and that Gs is required and sufficient while β-arrestin is not. The internalized AC9 contributes to cAMP production stemming from intracellular receptors. While Gs-induced AC9 endocytosis is independent of cAMP production, the actual mechanism linking Gs activation to AC9 endocytosis remains unknown.</p><p>Overall the work shows Gs activation during β-adrenergic receptor signaling drives endosomal localization of the downstream effector AC9. The reviews were positive. The experiments are well-controlled, show mostly clear effects, and are convincing for the system being investigated. Nevertheless, certain conceptual and technical issues were raised that need to be addressed prior to publication.</p><p>Essential revisions:</p><p>1) The β2AR is not the prototypical GPCR for studying sustained cAMP generation from endosomes. Although the authors present some data for the V2R that has been previously shown to induce very sustained cAMP responses, it is well-known that several class A or B GPCRs possess this feature as well and to a far greater extent than that observed for the β2AR. If at all possible, the study would benefit from control experiments using another GPCR class A (e.g., TSHR) or class B (e.g., GLP-1R, PAC1R, CTR), which would more broadly determine how generalizable these findings are. Additionally, the authors should put forth a rationale as to why they selected the β2AR for this study as opposed to the more canonical receptors mentioned above.</p><p>2) All fluorescence images shown in the main figures are confocal images, however the quantification data presented in the main figures were obtained from widefield images shown in supplementary figures. While confocal images show a clear internalization of both HA-β2AR and Flag-AC9, the widefield images have high levels of background, which can make particle tracking more difficult. Some concerns about this:</p><p>– What's the reason behind choosing to quantify images acquired by widefield and show representative confocal images? The type of microscopy used could affect particle tracking, especially when we consider the lower resolution in widefield compared to confocal.</p><p>– Widefield is a great choice for live cell imaging, however, most of these experiments were done in fixed cells. Confocal will show &quot;better&quot; endosomes. Quantification should be done with confocal images.</p><p>– While authors provided a satisfactory statistics analysis, all &quot;representative&quot; images and curves (for cAMP production) do not have an 'n'. How many times were these experiments repeated?</p><p>– Quantification of fluorescence images and representative images should be done with images acquired by the same microscopy method to avoid differences based on the nature of microscopy kind.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.58039.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) The β2AR is not the prototypical GPCR for studying sustained cAMP generation from endosomes. Although the authors present some data for the V2R that has been previously shown to induce very sustained cAMP responses, it is well-known that several class A or B GPCRs possess this feature as well and to a far greater extent than that observed for the β2AR. If at all possible, the study would benefit from control experiments using another GPCR class A (e.g., TSHR) or class B (e.g., GLP-1R, PAC1R, CTR), which would more broadly determine how generalizable these findings are. Additionally, the authors should put forth a rationale as to why they selected the β2AR for this study as opposed to the more canonical receptors mentioned above.</p></disp-quote><p>We agree that the B2AR is not a prototype for sustained signaling. Instead, β-2 receptors provide an example of GPCRs which cycle rapidly and continuously through endosomes, activating Gs transiently each round. The B2AR is also widely recognized not to recruit β-arrestins to endosomes, in contrast to some other GPCRs with longer residence in endosomes which have been shown to mediate a sustained cAMP response.</p><p>However, we do not believe that these considerations negate the importance of endosomal signaling stimulated by the B2AR. Previously published data (Irannejad et al., 2013, cited in the text), showed that endosomal activation of the B2AR mediates a detectable (albeit moderate) contribution to (transient) global cAMP elevation. We have also shown that this is required for the cAMP-dependent transcriptional response elicited by endogenous B2AR activation (Tsvetanova et al., 2014, also cited). We independently verify in the present study that β-2 receptor activation in endosomes makes a significant (yet rapidly reversible) contribution to the global cellular cAMP response, and provide new data showing that this component of transient cAMP signaling requires AC9.</p><p>Nevertheless, we agree that the results summarized above do not necessarily mean that AC9 is also relevant to signaling by GPCRs that mediate sustained Gs activation, and that we failed to address in the initial submission. In the revised manuscript we explicitly note and cite that signaling initiated from endosomes can be transient or sustained (Introduction, second paragraph), and that the V2 vasopressin receptor (V2R) mediates sustained signaling (–subsection “AC9 trafficking is stimulated by GPCRs coupled to Gs but not Gi”, first paragraph). We demonstrate in the present study that V2Rs are indeed capable of driving AC9 trafficking in 293 cells when recombinantly expressed in these cells, similarly to recombinantly expressed B2ARs which define our primary focus.</p><p>We also show that a V2R truncation mutant can drive AC9 trafficking. We focused on this observation as an initial clue to a separation between receptor and AC9 trafficking. However this mutant receptor is also well known to lose its ‘class B’ phenotype (β-arrestin recruitment to endosomes) and recycle more rapidly than wild-type V2R. We have modified the text to explicitly point this out in the revised Results section (–subsection “AC9 trafficking is stimulated by GPCRs coupled to Gs but not Gi”, last paragraph). We believe that these results provide additional, independent support for our conclusion that AC9 trafficking is not restricted to the β-2 adrenergic receptor or to rapidly recycling / transiently signaling GPCRs. This is also consistent with the ability of receptor-independent activation of Gs (mutationally or using cholera toxin) to stimulate AC9 trafficking, as was already shown and discussed in the manuscript.</p><disp-quote content-type="editor-comment"><p>2) All fluorescence images shown in the main figures are confocal images, however the quantification data presented in the main figures were obtained from widefield images shown in supplementary figures. While confocal images show a clear internalization of both HA-β2AR and Flag-AC9, the widefield images have high levels of background, which can make particle tracking more difficult. Some concerns about this:</p><p>– What's the reason behind choosing to quantify images acquired by widefield and show representative confocal images? The type of microscopy used could affect particle tracking, especially when we consider the lower resolution in widefield compared to confocal.</p><p>– Widefield is a great choice for live cell imaging, however, most of these experiments were done in fixed cells. Confocal will show &quot;better&quot; endosomes. Quantification should be done with confocal images.</p><p>– While authors provided a satisfactory statistics analysis, all &quot;representative&quot; images and curves (for cAMP production) do not have an 'n'. How many times were these experiments repeated?</p><p>– Quantification of fluorescence images and representative images should be done with images acquired by the same microscopy method to avoid differences based on the nature of microscopy kind.</p></disp-quote><p>The reason that we show wide field images is to verify the trafficking behavior over large cell ‘lawns’ and to indicate that the trafficking phenotype is robust and consistent across cells. We also think this is useful because, as the reviewers indicate, widefield is less sensitive for detecting internalization effects relative to confocal (which can emphasize internal structures depending on the plane of section). We think the fact that one can easily see the trafficking phenotype with low-mag widefield imaging is significant and may be relevant for those investigators who lack routine access to a confocal microscope or objectives with sufficiently high magnification / numerical aperture to resolve individual endosomes as the reviewers indicate. Actually we do show (in the main figures) multiple examples of such higher-resolution images, but this is not the point of including the lower resolution images of cell lawns in the supplement. We also agree that quantifying more confocal images could provide additional support, but again this was not the purpose of including widefield images. In fact we believe that the (two) biochemical approaches used (surface biotinylation and endosome isolation) more incisively establish internalization of AC9. To clarify this, in the revised manuscript we more fully explained our rationale for showing lower-resolution images in data supplement (subsection “Regulated and isoform-selective trafficking of AC9 to endosomes”, second paragraph).</p></body></sub-article></article>